WO2020242245A1 - 프탈라진온 화합물 및 이들의 용도 - Google Patents
프탈라진온 화합물 및 이들의 용도 Download PDFInfo
- Publication number
- WO2020242245A1 WO2020242245A1 PCT/KR2020/006995 KR2020006995W WO2020242245A1 WO 2020242245 A1 WO2020242245 A1 WO 2020242245A1 KR 2020006995 W KR2020006995 W KR 2020006995W WO 2020242245 A1 WO2020242245 A1 WO 2020242245A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- phenyl
- dihydrophthalazine
- fluorophenyl
- dihydrophthalazin
- Prior art date
Links
- IJAPPYDYQCXOEF-UHFFFAOYSA-N phthalazin-1(2H)-one Chemical class C1=CC=C2C(=O)NN=CC2=C1 IJAPPYDYQCXOEF-UHFFFAOYSA-N 0.000 title 1
- 150000003839 salts Chemical class 0.000 claims abstract description 49
- 101150109526 Sirt6 gene Proteins 0.000 claims abstract description 32
- -1 phthalazinone compound Chemical class 0.000 claims abstract description 29
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 238000000034 method Methods 0.000 claims abstract description 23
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 150000001875 compounds Chemical class 0.000 claims description 506
- 125000000217 alkyl group Chemical group 0.000 claims description 106
- 125000003118 aryl group Chemical group 0.000 claims description 52
- 229910052799 carbon Inorganic materials 0.000 claims description 36
- 125000001072 heteroaryl group Chemical group 0.000 claims description 36
- 125000000623 heterocyclic group Chemical group 0.000 claims description 29
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 19
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 19
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001153 fluoro group Chemical group F* 0.000 claims description 16
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000001246 bromo group Chemical group Br* 0.000 claims description 12
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 12
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- JXUMIBKMIPZILJ-UHFFFAOYSA-N C1CC(CN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C5(CC5)C(=O)O Chemical compound C1CC(CN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C5(CC5)C(=O)O JXUMIBKMIPZILJ-UHFFFAOYSA-N 0.000 claims description 9
- LQJZJWVYJQWECB-UHFFFAOYSA-N CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O Chemical compound CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O LQJZJWVYJQWECB-UHFFFAOYSA-N 0.000 claims description 9
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- UHQPQZSSRPQAPN-UHFFFAOYSA-N C1CC(C1)(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O Chemical compound C1CC(C1)(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O UHQPQZSSRPQAPN-UHFFFAOYSA-N 0.000 claims description 6
- SRQUNIVLJZCCFD-XFULWGLBSA-N CN[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound CN[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl SRQUNIVLJZCCFD-XFULWGLBSA-N 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 5
- FZVADLVQTJFMNP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC=CC(=C4)C#N Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC=CC(=C4)C#N FZVADLVQTJFMNP-UHFFFAOYSA-N 0.000 claims description 5
- UDFUOJROPHGNMP-UHFFFAOYSA-N CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)O Chemical compound CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)O UDFUOJROPHGNMP-UHFFFAOYSA-N 0.000 claims description 5
- MCKONFBFIFKCLE-DICXZTSXSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] MCKONFBFIFKCLE-DICXZTSXSA-N 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims description 4
- IDPNXRBDZWTROJ-QFEZKATASA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] IDPNXRBDZWTROJ-QFEZKATASA-N 0.000 claims description 4
- BZAXYJQVKDCLST-FSGOGVSDSA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5)/[O-] BZAXYJQVKDCLST-FSGOGVSDSA-N 0.000 claims description 4
- YDJZVHFNRNDTKA-QFEZKATASA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] YDJZVHFNRNDTKA-QFEZKATASA-N 0.000 claims description 4
- MTMPBAAOEJXPBZ-IWIPYMOSSA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)/[O-] MTMPBAAOEJXPBZ-IWIPYMOSSA-N 0.000 claims description 4
- DBKRHKYWHBDGRQ-QFEZKATASA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] DBKRHKYWHBDGRQ-QFEZKATASA-N 0.000 claims description 4
- MWGVVUWHPFEABF-QFEZKATASA-N C/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound C/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] MWGVVUWHPFEABF-QFEZKATASA-N 0.000 claims description 4
- OOYGZYOUUHXFEV-AFUMVMLFSA-N C/[N+](=C\C1=CC=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound C/[N+](=C\C1=CC=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] OOYGZYOUUHXFEV-AFUMVMLFSA-N 0.000 claims description 4
- WXSAXWPTGYFWIW-DXJNIWACSA-N C1=CC=C(C=C1)C/[N+](=C/C2=CC(=CC=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)/[O-] Chemical compound C1=CC=C(C=C1)C/[N+](=C/C2=CC(=CC=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)/[O-] WXSAXWPTGYFWIW-DXJNIWACSA-N 0.000 claims description 4
- YDXMTYNPEJISHC-COEJQBHMSA-N C1=CC=C(C=C1)C/[N+](=C/C2=CC(=CC=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=CC=C5)/[O-] Chemical compound C1=CC=C(C=C1)C/[N+](=C/C2=CC(=CC=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=CC=C5)/[O-] YDXMTYNPEJISHC-COEJQBHMSA-N 0.000 claims description 4
- LPDQLRSXVQGNFH-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)N Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)N LPDQLRSXVQGNFH-UHFFFAOYSA-N 0.000 claims description 4
- CCNLAEXPIWBSBC-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC=CC(=C4)CC(=O)O Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC=CC(=C4)CC(=O)O CCNLAEXPIWBSBC-UHFFFAOYSA-N 0.000 claims description 4
- LNZOMRROGJBXRR-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CN=CC=C4 Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CN=CC=C4 LNZOMRROGJBXRR-UHFFFAOYSA-N 0.000 claims description 4
- MOFYLRKRQYCORJ-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=C[N+](=CC=C4)[O-] Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=C[N+](=CC=C4)[O-] MOFYLRKRQYCORJ-UHFFFAOYSA-N 0.000 claims description 4
- CJBDWWDETMNIBG-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)C4=CN=CC=C4 Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)C4=CN=CC=C4 CJBDWWDETMNIBG-UHFFFAOYSA-N 0.000 claims description 4
- RXPBRJGIMKRPAS-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)C4=C[N+](=CC=C4)[O-] Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)C4=C[N+](=CC=C4)[O-] RXPBRJGIMKRPAS-UHFFFAOYSA-N 0.000 claims description 4
- LODZWDGVXQSXGJ-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)Cl)[N+](=O)[O-] Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=C(C=C4)Cl)[N+](=O)[O-] LODZWDGVXQSXGJ-UHFFFAOYSA-N 0.000 claims description 4
- DMGPJSXFSCNPAI-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)NO Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C(=O)NO DMGPJSXFSCNPAI-UHFFFAOYSA-N 0.000 claims description 4
- YCDFVNMCYOOOOG-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C5=NNN=N5 Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)C5=NNN=N5 YCDFVNMCYOOOOG-UHFFFAOYSA-N 0.000 claims description 4
- GLUMZEZIRRMPLU-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)N Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)N GLUMZEZIRRMPLU-UHFFFAOYSA-N 0.000 claims description 4
- BJKITUBPQAQCGD-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=C[N+](=CC=C4)[O-] Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=C[N+](=CC=C4)[O-] BJKITUBPQAQCGD-UHFFFAOYSA-N 0.000 claims description 4
- PNSKBJGWDIGJKB-UHFFFAOYSA-N C1CC(CN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)N.Cl Chemical compound C1CC(CN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)N.Cl PNSKBJGWDIGJKB-UHFFFAOYSA-N 0.000 claims description 4
- VWSZLNYTOKFQGU-UHFFFAOYSA-N C1CC1(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O Chemical compound C1CC1(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O VWSZLNYTOKFQGU-UHFFFAOYSA-N 0.000 claims description 4
- XXDVUUFJIBUYFJ-UHFFFAOYSA-N C1CC1(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl)C(=O)O Chemical compound C1CC1(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl)C(=O)O XXDVUUFJIBUYFJ-UHFFFAOYSA-N 0.000 claims description 4
- BNZKZNAQGDLODE-UHFFFAOYSA-N C1CC1S(=O)(=O)NC2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F Chemical compound C1CC1S(=O)(=O)NC2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F BNZKZNAQGDLODE-UHFFFAOYSA-N 0.000 claims description 4
- GNSMUKXCWWFAAW-UHFFFAOYSA-N C1CCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCCC(C4)N.Cl Chemical compound C1CCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCCC(C4)N.Cl GNSMUKXCWWFAAW-UHFFFAOYSA-N 0.000 claims description 4
- UBKJDUXMTPSFEW-UHFFFAOYSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCCC(C4)N.Cl Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCCC(C4)N.Cl UBKJDUXMTPSFEW-UHFFFAOYSA-N 0.000 claims description 4
- UBKJDUXMTPSFEW-RSAXXLAASA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCC[C@@H](C4)N.Cl Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCC[C@@H](C4)N.Cl UBKJDUXMTPSFEW-RSAXXLAASA-N 0.000 claims description 4
- UBKJDUXMTPSFEW-XFULWGLBSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCC[C@H](C4)N.Cl Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCCC[C@H](C4)N.Cl UBKJDUXMTPSFEW-XFULWGLBSA-N 0.000 claims description 4
- GOSLVYLJYSKQAG-UQKRIMTDSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCC[C@@H](C4)N.Cl Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)N4CCC[C@@H](C4)N.Cl GOSLVYLJYSKQAG-UQKRIMTDSA-N 0.000 claims description 4
- FWDZTAYPNSCCPL-UHFFFAOYSA-N C1CCN(C1)S(=O)(=O)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F Chemical compound C1CCN(C1)S(=O)(=O)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F FWDZTAYPNSCCPL-UHFFFAOYSA-N 0.000 claims description 4
- GUNJWIMLQRAFOY-UHFFFAOYSA-N C1CCN(CC(=O)C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound C1CCN(CC(=O)C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F GUNJWIMLQRAFOY-UHFFFAOYSA-N 0.000 claims description 4
- TYPHTSDNWPRIEP-UHFFFAOYSA-N C1CCN(CC(C1)C#N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)Cl)F Chemical compound C1CCN(CC(C1)C#N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)Cl)F TYPHTSDNWPRIEP-UHFFFAOYSA-N 0.000 claims description 4
- QBQSGSXAHNMNGE-UHFFFAOYSA-N C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl QBQSGSXAHNMNGE-UHFFFAOYSA-N 0.000 claims description 4
- NGSFNMKDMNHVIM-UHFFFAOYSA-N C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl Chemical compound C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl NGSFNMKDMNHVIM-UHFFFAOYSA-N 0.000 claims description 4
- KJHCPRHJCWZYIJ-UHFFFAOYSA-N C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4CCC4.Cl Chemical compound C1CCN(CC(C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4CCC4.Cl KJHCPRHJCWZYIJ-UHFFFAOYSA-N 0.000 claims description 4
- NFWQYFGFTKVGGB-UHFFFAOYSA-N C1CCN(CC(C1)O)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl Chemical compound C1CCN(CC(C1)O)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl NFWQYFGFTKVGGB-UHFFFAOYSA-N 0.000 claims description 4
- QBQSGSXAHNMNGE-PFEQFJNWSA-N C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl QBQSGSXAHNMNGE-PFEQFJNWSA-N 0.000 claims description 4
- YPNLHJUTEWYQKE-XFULWGLBSA-N C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl.Cl Chemical compound C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl.Cl YPNLHJUTEWYQKE-XFULWGLBSA-N 0.000 claims description 4
- NGSFNMKDMNHVIM-XFULWGLBSA-N C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl Chemical compound C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl NGSFNMKDMNHVIM-XFULWGLBSA-N 0.000 claims description 4
- YVXAGRQSNKPERF-PFEQFJNWSA-N C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F.Cl Chemical compound C1CCN(C[C@@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F.Cl YVXAGRQSNKPERF-PFEQFJNWSA-N 0.000 claims description 4
- XLQKZPSKOLDMTF-PKLMIRHRSA-N C1CCN(C[C@@H](C1)NCCO)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CCN(C[C@@H](C1)NCCO)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl XLQKZPSKOLDMTF-PKLMIRHRSA-N 0.000 claims description 4
- QBQSGSXAHNMNGE-UQKRIMTDSA-N C1CCN(C[C@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CCN(C[C@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl QBQSGSXAHNMNGE-UQKRIMTDSA-N 0.000 claims description 4
- NGSFNMKDMNHVIM-RSAXXLAASA-N C1CCN(C[C@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl Chemical compound C1CCN(C[C@H](C1)N)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F.Cl NGSFNMKDMNHVIM-RSAXXLAASA-N 0.000 claims description 4
- OYCZHRKFDIUVIX-UHFFFAOYSA-N C1CNCC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CNCC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl OYCZHRKFDIUVIX-UHFFFAOYSA-N 0.000 claims description 4
- VXSGUQKZHINRPR-UHFFFAOYSA-N C1CNCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound C1CNCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl VXSGUQKZHINRPR-UHFFFAOYSA-N 0.000 claims description 4
- QDZLEQFGWMPFLT-UHFFFAOYSA-N C1COC(=O)N1C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F Chemical compound C1COC(=O)N1C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F QDZLEQFGWMPFLT-UHFFFAOYSA-N 0.000 claims description 4
- YMJBIPVMTLNHGD-UHFFFAOYSA-N CC(C)(C#N)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CC(C)(C#N)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F YMJBIPVMTLNHGD-UHFFFAOYSA-N 0.000 claims description 4
- URVDTECJIZNTBI-FDVSRXAVSA-N CC(C)(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] URVDTECJIZNTBI-FDVSRXAVSA-N 0.000 claims description 4
- YOGXMCRWGRZQDS-NTFVMDSBSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] YOGXMCRWGRZQDS-NTFVMDSBSA-N 0.000 claims description 4
- NXOCSODMVIBGTA-NTFVMDSBSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] NXOCSODMVIBGTA-NTFVMDSBSA-N 0.000 claims description 4
- WZWSJQMMZJHENW-NTFVMDSBSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] WZWSJQMMZJHENW-NTFVMDSBSA-N 0.000 claims description 4
- VIWRLGDCISFHHN-WGARJPEWSA-N CC(C)(C)/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] VIWRLGDCISFHHN-WGARJPEWSA-N 0.000 claims description 4
- WUJNOFAPRRNTGA-NTFVMDSBSA-N CC(C)(C)/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] WUJNOFAPRRNTGA-NTFVMDSBSA-N 0.000 claims description 4
- NQGZHAZJLMFXEJ-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)Cl)F)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)Cl)F)C(=O)O NQGZHAZJLMFXEJ-UHFFFAOYSA-N 0.000 claims description 4
- OXHBOZCWWZCYLU-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)N Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)N OXHBOZCWWZCYLU-UHFFFAOYSA-N 0.000 claims description 4
- UJCZSNJXTJIAAY-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5CCCCC5 Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5CCCCC5 UJCZSNJXTJIAAY-UHFFFAOYSA-N 0.000 claims description 4
- WPYFKFAWXPHBPD-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O WPYFKFAWXPHBPD-UHFFFAOYSA-N 0.000 claims description 4
- ATOWMFXGIKDFRC-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C5=NNN=N5 Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C5=NNN=N5 ATOWMFXGIKDFRC-UHFFFAOYSA-N 0.000 claims description 4
- NPXJXXRBCSHNCK-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)N.Cl Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)N.Cl NPXJXXRBCSHNCK-UHFFFAOYSA-N 0.000 claims description 4
- KSBVDVLNPFSFRN-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5CC5)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5CC5)C(=O)O KSBVDVLNPFSFRN-UHFFFAOYSA-N 0.000 claims description 4
- ZBNGGQVVUSNHDZ-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)N Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)N ZBNGGQVVUSNHDZ-UHFFFAOYSA-N 0.000 claims description 4
- PKUDLSNGRINHLH-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)Cl)C(=O)O PKUDLSNGRINHLH-UHFFFAOYSA-N 0.000 claims description 4
- VTQUYJPAUDXTSY-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)C(=O)NC Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)C(=O)NC VTQUYJPAUDXTSY-UHFFFAOYSA-N 0.000 claims description 4
- SMBYLFTUHACUPU-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)C(=O)O SMBYLFTUHACUPU-UHFFFAOYSA-N 0.000 claims description 4
- HCAIZGKWCRHFRN-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)C(=O)O HCAIZGKWCRHFRN-UHFFFAOYSA-N 0.000 claims description 4
- OMSNMEMPKZDUIJ-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)N Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)N OMSNMEMPKZDUIJ-UHFFFAOYSA-N 0.000 claims description 4
- FUVAKZHSDKBNHH-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)NC Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)NC FUVAKZHSDKBNHH-UHFFFAOYSA-N 0.000 claims description 4
- AXUNYKPRFWMPIR-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)O Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4)C(=O)O AXUNYKPRFWMPIR-UHFFFAOYSA-N 0.000 claims description 4
- OMOFJLGRFZZBSY-UHFFFAOYSA-N CC(C)(CN)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl Chemical compound CC(C)(CN)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F.Cl OMOFJLGRFZZBSY-UHFFFAOYSA-N 0.000 claims description 4
- GNZLVSGAZDNIGN-MUXKCCDJSA-N CC(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] GNZLVSGAZDNIGN-MUXKCCDJSA-N 0.000 claims description 4
- XKAVHOXDQNONAU-MUXKCCDJSA-N CC(C)/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] XKAVHOXDQNONAU-MUXKCCDJSA-N 0.000 claims description 4
- SXIQLMCAFBMSNX-MUXKCCDJSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] SXIQLMCAFBMSNX-MUXKCCDJSA-N 0.000 claims description 4
- LNDCZYZKMARCFA-MUXKCCDJSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] LNDCZYZKMARCFA-MUXKCCDJSA-N 0.000 claims description 4
- QRQYJBAVAURBMQ-MUXKCCDJSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC(=C4)F)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC(=C4)F)F)/[O-] QRQYJBAVAURBMQ-MUXKCCDJSA-N 0.000 claims description 4
- RDETTXHQJYBNHM-RGXNXFOYSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5)/[O-] RDETTXHQJYBNHM-RGXNXFOYSA-N 0.000 claims description 4
- SMJTZSQBAONFSO-QQXSKIMKSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)/[O-] SMJTZSQBAONFSO-QQXSKIMKSA-N 0.000 claims description 4
- NSXUZJBVJZFWPN-MXAYSNPKSA-N CC(C)/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] NSXUZJBVJZFWPN-MXAYSNPKSA-N 0.000 claims description 4
- JPOKNWPKEHPJHY-CCVNUDIWSA-N CC(C)/[N+](=C\C1=CC(=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] Chemical compound CC(C)/[N+](=C\C1=CC(=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] JPOKNWPKEHPJHY-CCVNUDIWSA-N 0.000 claims description 4
- NTBXXTMYZZJPOP-UHFFFAOYSA-N CC(C)S(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CC(C)S(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F NTBXXTMYZZJPOP-UHFFFAOYSA-N 0.000 claims description 4
- UZLAHCMZQGTMMQ-UHFFFAOYSA-N CC(C)S(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CC(C)S(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F UZLAHCMZQGTMMQ-UHFFFAOYSA-N 0.000 claims description 4
- YJLYPUNCHSAQLA-YSMPRRRNSA-N CC/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] YJLYPUNCHSAQLA-YSMPRRRNSA-N 0.000 claims description 4
- BBGCOKDWJCCAOK-UHFFFAOYSA-N CCCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F BBGCOKDWJCCAOK-UHFFFAOYSA-N 0.000 claims description 4
- UFDVYLJFUQMOTA-UHFFFAOYSA-N CCCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F UFDVYLJFUQMOTA-UHFFFAOYSA-N 0.000 claims description 4
- LUXMLWZTXJNWFE-UHFFFAOYSA-N CCN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F LUXMLWZTXJNWFE-UHFFFAOYSA-N 0.000 claims description 4
- XKKGSAJPXXSIHM-UHFFFAOYSA-N CCN(CC)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCN(CC)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F XKKGSAJPXXSIHM-UHFFFAOYSA-N 0.000 claims description 4
- FIKMUDOPGLPTNE-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F FIKMUDOPGLPTNE-UHFFFAOYSA-N 0.000 claims description 4
- NLENCBGROVNNTE-UHFFFAOYSA-N CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F NLENCBGROVNNTE-UHFFFAOYSA-N 0.000 claims description 4
- RCDRLMHCQNXJSP-UHFFFAOYSA-N CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F RCDRLMHCQNXJSP-UHFFFAOYSA-N 0.000 claims description 4
- KUWPBHJIVHKQKB-UHFFFAOYSA-N CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F Chemical compound CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F KUWPBHJIVHKQKB-UHFFFAOYSA-N 0.000 claims description 4
- KNVIEQDDVGOULJ-UHFFFAOYSA-N CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F Chemical compound CCS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F KNVIEQDDVGOULJ-UHFFFAOYSA-N 0.000 claims description 4
- UXPHEUSDKLPHAO-UHFFFAOYSA-N CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F UXPHEUSDKLPHAO-UHFFFAOYSA-N 0.000 claims description 4
- XFEKQRTYZDNFQB-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 Chemical compound CCS(=O)(=O)NC1=CC=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 XFEKQRTYZDNFQB-UHFFFAOYSA-N 0.000 claims description 4
- VSJNLBZYNZASMZ-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=CN(C(=O)C3=C2C=NC=C3)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=CN(C(=O)C3=C2C=NC=C3)C4=CC=C(C=C4)F VSJNLBZYNZASMZ-UHFFFAOYSA-N 0.000 claims description 4
- SAMTUYGBBBSIJJ-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC(=C32)C)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC(=C32)C)C4=CC=C(C=C4)F SAMTUYGBBBSIJJ-UHFFFAOYSA-N 0.000 claims description 4
- FVWAUNHKVFVULL-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C(C)C Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C(C)C FVWAUNHKVFVULL-UHFFFAOYSA-N 0.000 claims description 4
- FWGZNYXWFRZKKU-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F FWGZNYXWFRZKKU-UHFFFAOYSA-N 0.000 claims description 4
- YNIUUSJZOVAQBH-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F YNIUUSJZOVAQBH-UHFFFAOYSA-N 0.000 claims description 4
- AIHGCAPHKJEMOJ-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F AIHGCAPHKJEMOJ-UHFFFAOYSA-N 0.000 claims description 4
- XJZGUBZHXRKTRX-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 XJZGUBZHXRKTRX-UHFFFAOYSA-N 0.000 claims description 4
- KEKQMTLDSIPQPF-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCC(CC4)(F)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCC(CC4)(F)F KEKQMTLDSIPQPF-UHFFFAOYSA-N 0.000 claims description 4
- CENLLMXUJZWHRQ-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCC(CC4)C Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCC(CC4)C CENLLMXUJZWHRQ-UHFFFAOYSA-N 0.000 claims description 4
- WDTCNSOUDYSFLO-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 WDTCNSOUDYSFLO-UHFFFAOYSA-N 0.000 claims description 4
- POHNNBJEYWBRES-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCN(CC4)C Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCN(CC4)C POHNNBJEYWBRES-UHFFFAOYSA-N 0.000 claims description 4
- PLRCPCVSUZJDAY-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCOCC4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCOCC4 PLRCPCVSUZJDAY-UHFFFAOYSA-N 0.000 claims description 4
- RZZVQJZVHSMGDB-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4COC4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4COC4 RZZVQJZVHSMGDB-UHFFFAOYSA-N 0.000 claims description 4
- ITLNJDRZHNBVDG-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CC4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CC4=CC=C(C=C4)F ITLNJDRZHNBVDG-UHFFFAOYSA-N 0.000 claims description 4
- ZQWFYZYQOQRMNF-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CCC4=CC=CC=C4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CCC4=CC=CC=C4 ZQWFYZYQOQRMNF-UHFFFAOYSA-N 0.000 claims description 4
- BIKLCEOEGORYBW-UHFFFAOYSA-N CCS(=O)(=O)NC1=CN=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1=CN=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F BIKLCEOEGORYBW-UHFFFAOYSA-N 0.000 claims description 4
- YKWZTSHYGGQWEN-UHFFFAOYSA-N CCS(=O)(=O)NC1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F YKWZTSHYGGQWEN-UHFFFAOYSA-N 0.000 claims description 4
- SSRBYXLOWZIMNE-UHFFFAOYSA-N CCS(=O)(=O)NC1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 Chemical compound CCS(=O)(=O)NC1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 SSRBYXLOWZIMNE-UHFFFAOYSA-N 0.000 claims description 4
- IZEDVFNPRKQQKN-UHFFFAOYSA-N CCS(=O)(=O)NC1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F IZEDVFNPRKQQKN-UHFFFAOYSA-N 0.000 claims description 4
- DLEYOONSWNBLFE-UHFFFAOYSA-N CCS(=O)(=O)NC1CCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1CCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F DLEYOONSWNBLFE-UHFFFAOYSA-N 0.000 claims description 4
- KTWDVHJQIXRVQQ-INIZCTEOSA-N CCS(=O)(=O)N[C@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 Chemical compound CCS(=O)(=O)N[C@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 KTWDVHJQIXRVQQ-INIZCTEOSA-N 0.000 claims description 4
- MXUXEIDTAZUXJX-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F MXUXEIDTAZUXJX-UHFFFAOYSA-N 0.000 claims description 4
- YERSNEFTXBRMMM-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F YERSNEFTXBRMMM-UHFFFAOYSA-N 0.000 claims description 4
- UKDHMAREYIFLJL-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F Chemical compound CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F UKDHMAREYIFLJL-UHFFFAOYSA-N 0.000 claims description 4
- UAQISRQYXDKTBD-UHFFFAOYSA-N CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F Chemical compound CN(C)S(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F UAQISRQYXDKTBD-UHFFFAOYSA-N 0.000 claims description 4
- HDQHUGOCIMYCHN-UHFFFAOYSA-N CN(C)S(=O)(=O)NC1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)Cl Chemical compound CN(C)S(=O)(=O)NC1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)Cl HDQHUGOCIMYCHN-UHFFFAOYSA-N 0.000 claims description 4
- SUOSCMCWXXCHMV-UHFFFAOYSA-N CN(C)S(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CN(C)S(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F SUOSCMCWXXCHMV-UHFFFAOYSA-N 0.000 claims description 4
- UQDPIQGTHIGQFV-UHFFFAOYSA-N CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C Chemical compound CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C UQDPIQGTHIGQFV-UHFFFAOYSA-N 0.000 claims description 4
- RZCUHPUYFUWTRI-UHFFFAOYSA-N CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C5CC5 Chemical compound CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C5CC5 RZCUHPUYFUWTRI-UHFFFAOYSA-N 0.000 claims description 4
- DGFOVNHCTIPHQC-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F DGFOVNHCTIPHQC-UHFFFAOYSA-N 0.000 claims description 4
- YWDBAAWWRPIISV-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=CC=CC=C4 Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=CC=CC=C4 YWDBAAWWRPIISV-UHFFFAOYSA-N 0.000 claims description 4
- YBZCPOKDXORYIX-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=C(C=C(C=C4)F)F YBZCPOKDXORYIX-UHFFFAOYSA-N 0.000 claims description 4
- DPCNUEMQDDJHQF-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=CC=CC=C4 Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=CC=CC=C4 DPCNUEMQDDJHQF-UHFFFAOYSA-N 0.000 claims description 4
- FIYMMQITZPYRIG-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F FIYMMQITZPYRIG-UHFFFAOYSA-N 0.000 claims description 4
- GEZJSMBHJTWDNP-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F GEZJSMBHJTWDNP-UHFFFAOYSA-N 0.000 claims description 4
- ZMRWQXXNOLKKKW-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F ZMRWQXXNOLKKKW-UHFFFAOYSA-N 0.000 claims description 4
- XHAAWOKBMSAQDV-NTISSMGPSA-N CN[C@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4.Cl Chemical compound CN[C@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4.Cl XHAAWOKBMSAQDV-NTISSMGPSA-N 0.000 claims description 4
- YHCXTMIJTUWHQD-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F YHCXTMIJTUWHQD-UHFFFAOYSA-N 0.000 claims description 4
- PBDYKDHNVUWFET-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=CC=CC=C4 Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=CC=CC=C4 PBDYKDHNVUWFET-UHFFFAOYSA-N 0.000 claims description 4
- VWTYCBCFZLNEQZ-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=C(C=C(C=C4)F)F VWTYCBCFZLNEQZ-UHFFFAOYSA-N 0.000 claims description 4
- RJCGVDKSQZWWLI-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=CC=CC=C4 Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=CC(=C3)F)C4=CC=CC=C4 RJCGVDKSQZWWLI-UHFFFAOYSA-N 0.000 claims description 4
- OAKOUUVTWDYUQG-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F OAKOUUVTWDYUQG-UHFFFAOYSA-N 0.000 claims description 4
- JWGAJMGQWJCZJK-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F JWGAJMGQWJCZJK-UHFFFAOYSA-N 0.000 claims description 4
- ZQPWEEQKJFQMAD-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F ZQPWEEQKJFQMAD-UHFFFAOYSA-N 0.000 claims description 4
- HLLHOYFTBCXPFZ-UHFFFAOYSA-N CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 Chemical compound CS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4CCCCC4 HLLHOYFTBCXPFZ-UHFFFAOYSA-N 0.000 claims description 4
- MZICWOCOHPGTQB-UHFFFAOYSA-N CS(=O)(=O)N(C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)Cl)S(=O)(=O)C Chemical compound CS(=O)(=O)N(C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)Cl)S(=O)(=O)C MZICWOCOHPGTQB-UHFFFAOYSA-N 0.000 claims description 4
- SVCKVAANFKCEDA-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F SVCKVAANFKCEDA-UHFFFAOYSA-N 0.000 claims description 4
- IAOCPCZILHXHCX-UHFFFAOYSA-N CS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 Chemical compound CS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4 IAOCPCZILHXHCX-UHFFFAOYSA-N 0.000 claims description 4
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- SAGOOAPUVYOCNV-UHFFFAOYSA-N methyl N-[[3-[3-(2,4-difluorophenyl)-4-oxophthalazin-1-yl]phenyl]sulfamoyl]carbamate Chemical compound COC(=O)NS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F SAGOOAPUVYOCNV-UHFFFAOYSA-N 0.000 claims description 4
- ZFYTWCMLKJUQDW-UHFFFAOYSA-N methyl N-[[3-[3-(4-fluorophenyl)-4-oxophthalazin-1-yl]phenyl]sulfamoyl]carbamate Chemical compound COC(=O)NS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F ZFYTWCMLKJUQDW-UHFFFAOYSA-N 0.000 claims description 4
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 3
- RJQGQDWPISNPNH-ZMFRSBBQSA-N C/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] Chemical compound C/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] RJQGQDWPISNPNH-ZMFRSBBQSA-N 0.000 claims description 3
- CYTLDYFGONKUMO-ZMFRSBBQSA-N C/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound C/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] CYTLDYFGONKUMO-ZMFRSBBQSA-N 0.000 claims description 3
- NFWGUYGKPSPJJZ-FMCGGJTJSA-N C/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound C/[N+](=C/C1=CC=C(S1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] NFWGUYGKPSPJJZ-FMCGGJTJSA-N 0.000 claims description 3
- UXPWTOHLUTZVPD-LGJNPRDNSA-N C/[N+](=C\C1=CC(=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] Chemical compound C/[N+](=C\C1=CC(=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)F)/[O-] UXPWTOHLUTZVPD-LGJNPRDNSA-N 0.000 claims description 3
- HRYKECOUGHXQQP-CAQPMQTCSA-N C1=CC=C(C=C1)C/[N+](=C/C2=CC(=C(C=C2)F)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)/[O-] Chemical compound C1=CC=C(C=C1)C/[N+](=C/C2=CC(=C(C=C2)F)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)/[O-] HRYKECOUGHXQQP-CAQPMQTCSA-N 0.000 claims description 3
- JLVGQLIHGRHHEH-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)S(=O)(=O)N Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)S(=O)(=O)N JLVGQLIHGRHHEH-UHFFFAOYSA-N 0.000 claims description 3
- NJJAJLNBNLNUFJ-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)S(=O)(=O)NCCO Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)C4=CC(=CC=C4)S(=O)(=O)NCCO NJJAJLNBNLNUFJ-UHFFFAOYSA-N 0.000 claims description 3
- ICHOOYCIEQTPCX-UHFFFAOYSA-N C1CC1(CC(=O)N)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl Chemical compound C1CC1(CC(=O)N)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl ICHOOYCIEQTPCX-UHFFFAOYSA-N 0.000 claims description 3
- UXNSBHSZBYVTMK-UHFFFAOYSA-N C1CCOC(C1)ONC(=O)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F Chemical compound C1CCOC(C1)ONC(=O)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F UXNSBHSZBYVTMK-UHFFFAOYSA-N 0.000 claims description 3
- FBABTPCKJQKEDH-MRXNPFEDSA-N CC(=O)N[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CC(=O)N[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F FBABTPCKJQKEDH-MRXNPFEDSA-N 0.000 claims description 3
- FVOQJZYGMRWXKM-MWLSYYOVSA-N CC(C)(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)OC)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=C(C=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)OC)/[O-] FVOQJZYGMRWXKM-MWLSYYOVSA-N 0.000 claims description 3
- ACGUDTQMFRHBMG-FDVSRXAVSA-N CC(C)(C)/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=C(C=C1)F)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] ACGUDTQMFRHBMG-FDVSRXAVSA-N 0.000 claims description 3
- JEESYVWCBNDPHS-FDVSRXAVSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] JEESYVWCBNDPHS-FDVSRXAVSA-N 0.000 claims description 3
- WJPNNSACMAUYRS-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5CC5 Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5CC5 WJPNNSACMAUYRS-UHFFFAOYSA-N 0.000 claims description 3
- AUBCZUUTSJMNAC-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NCCO Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NCCO AUBCZUUTSJMNAC-UHFFFAOYSA-N 0.000 claims description 3
- GUQDUUPZARHNES-UHFFFAOYSA-N CC(C)(C1CN(CCN1C)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O Chemical compound CC(C)(C1CN(CCN1C)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)O GUQDUUPZARHNES-UHFFFAOYSA-N 0.000 claims description 3
- ZNRVAUCMRLJUTC-MUXKCCDJSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=C(C=C4)F)Cl)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=C(C=C4)F)Cl)/[O-] ZNRVAUCMRLJUTC-MUXKCCDJSA-N 0.000 claims description 3
- WCNWOLWMBMETEX-MXAYSNPKSA-N CC(C)/[N+](=C/C1=CC=C(O1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC=C(O1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] WCNWOLWMBMETEX-MXAYSNPKSA-N 0.000 claims description 3
- UJHQXIPEOLAULI-UHFFFAOYSA-N CC1=NC(=NO1)C(C)(C)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F Chemical compound CC1=NC(=NO1)C(C)(C)C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F UJHQXIPEOLAULI-UHFFFAOYSA-N 0.000 claims description 3
- ZTCMZEWEAINFEU-UHFFFAOYSA-N CCNC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F Chemical compound CCNC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F ZTCMZEWEAINFEU-UHFFFAOYSA-N 0.000 claims description 3
- YPXXDUNFCQIXAZ-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=C2C=C(C=C3)F)C4=C(C=C(C=C4)F)F YPXXDUNFCQIXAZ-UHFFFAOYSA-N 0.000 claims description 3
- UOTJPKCXBPCJSH-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F UOTJPKCXBPCJSH-UHFFFAOYSA-N 0.000 claims description 3
- JXHJSSZMTJBHOV-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F JXHJSSZMTJBHOV-UHFFFAOYSA-N 0.000 claims description 3
- NPUSOOTUFSVDQW-UHFFFAOYSA-N CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F Chemical compound CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C(F)(F)F NPUSOOTUFSVDQW-UHFFFAOYSA-N 0.000 claims description 3
- DEQXLPKWIULQHB-UHFFFAOYSA-N CCS(=O)(=O)N1CCC(=CC1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCS(=O)(=O)N1CCC(=CC1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F DEQXLPKWIULQHB-UHFFFAOYSA-N 0.000 claims description 3
- ARRSTNHLIMDDOY-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5 ARRSTNHLIMDDOY-UHFFFAOYSA-N 0.000 claims description 3
- YKZIMQKXZQLNDK-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F YKZIMQKXZQLNDK-UHFFFAOYSA-N 0.000 claims description 3
- IZEDVFNPRKQQKN-MRXNPFEDSA-N CCS(=O)(=O)N[C@@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)N[C@@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F IZEDVFNPRKQQKN-MRXNPFEDSA-N 0.000 claims description 3
- IZEDVFNPRKQQKN-INIZCTEOSA-N CCS(=O)(=O)N[C@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound CCS(=O)(=O)N[C@H]1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F IZEDVFNPRKQQKN-INIZCTEOSA-N 0.000 claims description 3
- KQYNAMUWZKESMV-UHFFFAOYSA-N CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C(F)(F)F Chemical compound CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)C(F)(F)F KQYNAMUWZKESMV-UHFFFAOYSA-N 0.000 claims description 3
- KKRALRLEGJBRMR-UHFFFAOYSA-N CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F Chemical compound CNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F KKRALRLEGJBRMR-UHFFFAOYSA-N 0.000 claims description 3
- QBHSALDGEYOCDK-UHFFFAOYSA-N COC(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F Chemical compound COC(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F QBHSALDGEYOCDK-UHFFFAOYSA-N 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 125000001931 aliphatic group Chemical group 0.000 claims description 3
- 125000003277 amino group Chemical group 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 230000007882 cirrhosis Effects 0.000 claims description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 3
- 125000004122 cyclic group Chemical group 0.000 claims description 3
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 claims description 3
- 230000003914 insulin secretion Effects 0.000 claims description 3
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 2
- JLSNGBDYDWLYCQ-ZMFRSBBQSA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] JLSNGBDYDWLYCQ-ZMFRSBBQSA-N 0.000 claims description 2
- KDCJLWFEPDJKOR-ZMFRSBBQSA-N C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] Chemical compound C/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F)/[O-] KDCJLWFEPDJKOR-ZMFRSBBQSA-N 0.000 claims description 2
- JNXMZLDDSPRUKS-CAQPMQTCSA-N C1=CC=C(C=C1)C/[N+](=C/C2=C(C=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)F)/[O-] Chemical compound C1=CC=C(C=C1)C/[N+](=C/C2=C(C=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)F)F)/[O-] JNXMZLDDSPRUKS-CAQPMQTCSA-N 0.000 claims description 2
- YGRORZXMRDKZRB-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)NS(=O)(=O)C(F)(F)F Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)C4=CC(=CC=C4)NS(=O)(=O)C(F)(F)F YGRORZXMRDKZRB-UHFFFAOYSA-N 0.000 claims description 2
- HOIXWHPFSMNVGG-FDVSRXAVSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)/[O-] HOIXWHPFSMNVGG-FDVSRXAVSA-N 0.000 claims description 2
- UYYANJXGDSBIBF-FDVSRXAVSA-N CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=C(C=C4)F)Cl)/[O-] Chemical compound CC(C)(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=C(C=C4)F)Cl)/[O-] UYYANJXGDSBIBF-FDVSRXAVSA-N 0.000 claims description 2
- BRTSGJLZPCLUOO-YUMHPJSZSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)OC)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)OC)/[O-] BRTSGJLZPCLUOO-YUMHPJSZSA-N 0.000 claims description 2
- OTEQBVLSXSNXLE-DICXZTSXSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4F)/[O-] OTEQBVLSXSNXLE-DICXZTSXSA-N 0.000 claims description 2
- SHPGURSZESSBGZ-DICXZTSXSA-N CC(C)/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC=CC=C1C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/[O-] SHPGURSZESSBGZ-DICXZTSXSA-N 0.000 claims description 2
- YTZGIMJYXQKGHB-UHFFFAOYSA-N CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5 Chemical compound CCS(=O)(=O)N(C)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)C5=CC=CC=C5 YTZGIMJYXQKGHB-UHFFFAOYSA-N 0.000 claims description 2
- KBJNPAHHERCHBC-MRXNPFEDSA-N CCS(=O)(=O)N[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CCS(=O)(=O)N[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F KBJNPAHHERCHBC-MRXNPFEDSA-N 0.000 claims description 2
- VKZRDTOHIDMAGS-UHFFFAOYSA-N COC(=O)C1(CC1)C2CCCN(C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F Chemical compound COC(=O)C1(CC1)C2CCCN(C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F VKZRDTOHIDMAGS-UHFFFAOYSA-N 0.000 claims description 2
- FRCQVTXEWUICQV-MZFJOGFUSA-N COC1=C(C=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/C=[N+](/CC5=CC=CC=C5)\[O-] Chemical compound COC1=C(C=C(C=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)/C=[N+](/CC5=CC=CC=C5)\[O-] FRCQVTXEWUICQV-MZFJOGFUSA-N 0.000 claims description 2
- 125000003725 azepanyl group Chemical group 0.000 claims description 2
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims description 2
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- 125000002541 furyl group Chemical group 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 125000002636 imidazolinyl group Chemical group 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- XHSXSLVLMPYANK-UHFFFAOYSA-N methyl N-[[3-[3-(4-fluorophenyl)-4-oxophthalazin-1-yl]phenyl]-methylsulfamoyl]-N-methylcarbamate Chemical compound CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=C(C=C4)F)S(=O)(=O)N(C)C(=O)OC XHSXSLVLMPYANK-UHFFFAOYSA-N 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003566 oxetanyl group Chemical group 0.000 claims description 2
- 125000004193 piperazinyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 2
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 125000001422 pyrrolinyl group Chemical group 0.000 claims description 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 2
- 125000004306 triazinyl group Chemical group 0.000 claims description 2
- 125000005879 dioxolanyl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- WNSXUAGCWVZDQC-UHFFFAOYSA-N n-ethylbenzenesulfonamide Chemical compound CCNS(=O)(=O)C1=CC=CC=C1 WNSXUAGCWVZDQC-UHFFFAOYSA-N 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract description 6
- 239000004480 active ingredient Substances 0.000 abstract description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 274
- 239000007787 solid Substances 0.000 description 113
- 238000006243 chemical reaction Methods 0.000 description 71
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 52
- GNLVDIIYGZAWNY-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)Cl Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)F)Cl GNLVDIIYGZAWNY-UHFFFAOYSA-N 0.000 description 51
- 239000012044 organic layer Substances 0.000 description 51
- 239000011734 sodium Substances 0.000 description 51
- 238000002360 preparation method Methods 0.000 description 46
- 238000004440 column chromatography Methods 0.000 description 44
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- 239000008213 purified water Substances 0.000 description 41
- 239000000243 solution Substances 0.000 description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- QRADPBIYFJGSBH-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3C(F)(F)F)OS(=O)(=O)C(F)(F)F Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3C(F)(F)F)OS(=O)(=O)C(F)(F)F QRADPBIYFJGSBH-UHFFFAOYSA-N 0.000 description 32
- 239000007795 chemical reaction product Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 24
- 238000003756 stirring Methods 0.000 description 22
- 235000019439 ethyl acetate Nutrition 0.000 description 21
- HJBGZJMKTOMQRR-UHFFFAOYSA-N (3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C=O)=C1 HJBGZJMKTOMQRR-UHFFFAOYSA-N 0.000 description 20
- BYXUIKZQGOPKFR-UHFFFAOYSA-N hydron;n-propan-2-ylhydroxylamine;chloride Chemical compound Cl.CC(C)NO BYXUIKZQGOPKFR-UHFFFAOYSA-N 0.000 description 17
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 15
- JMZFEHDNIAQMNB-UHFFFAOYSA-N m-aminophenylboronic acid Chemical compound NC1=CC=CC(B(O)O)=C1 JMZFEHDNIAQMNB-UHFFFAOYSA-N 0.000 description 15
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 12
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 12
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 12
- BPKRRPYTIVGGIO-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)OS(=O)(=O)C(F)(F)F Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=C(C=CC=C3F)F)OS(=O)(=O)C(F)(F)F BPKRRPYTIVGGIO-UHFFFAOYSA-N 0.000 description 11
- DCSATTBHEMKGIP-UHFFFAOYSA-N n-tert-butylhydroxylamine;hydron;chloride Chemical compound Cl.CC(C)(C)NO DCSATTBHEMKGIP-UHFFFAOYSA-N 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 10
- LOOFMEVWCYVOJK-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3F)Cl Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3F)Cl LOOFMEVWCYVOJK-UHFFFAOYSA-N 0.000 description 10
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 10
- QCKGMJDOJRNSMS-UHFFFAOYSA-N 4-chloro-2h-phthalazin-1-one Chemical compound C1=CC=C2C(Cl)=NNC(=O)C2=C1 QCKGMJDOJRNSMS-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 150000001408 amides Chemical class 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- HZFFUMBZBGETES-UHFFFAOYSA-N (3-methylsulfonylphenyl)boronic acid Chemical compound CS(=O)(=O)C1=CC=CC(B(O)O)=C1 HZFFUMBZBGETES-UHFFFAOYSA-N 0.000 description 8
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 8
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 8
- JSWGCVVHHMENOS-UHFFFAOYSA-N C1=CC=C(C=C1)C2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C(=N3)Cl Chemical compound C1=CC=C(C=C1)C2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C(=N3)Cl JSWGCVVHHMENOS-UHFFFAOYSA-N 0.000 description 8
- QCPKGFZPEAIFCR-UHFFFAOYSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)Br Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)Br QCPKGFZPEAIFCR-UHFFFAOYSA-N 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- AQNQQHJNRPDOQV-UHFFFAOYSA-N bromocyclohexane Chemical compound BrC1CCCCC1 AQNQQHJNRPDOQV-UHFFFAOYSA-N 0.000 description 8
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 7
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 7
- IUSXOPNERIFVRV-UHFFFAOYSA-N [3-(methylsulfamoyl)phenyl]boronic acid Chemical compound CNS(=O)(=O)C1=CC=CC(B(O)O)=C1 IUSXOPNERIFVRV-UHFFFAOYSA-N 0.000 description 7
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 7
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 7
- 239000010977 jade Substances 0.000 description 7
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 7
- WIBKQUACEJUBPH-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=CC=C3)F)Cl Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=CC=C3)F)Cl WIBKQUACEJUBPH-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- NZEPWAXJSWYEDV-UHFFFAOYSA-N tert-butyl n-(azepan-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCCCNC1 NZEPWAXJSWYEDV-UHFFFAOYSA-N 0.000 description 6
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 6
- GWHLZOPSGWEFMF-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=O)N(N=C2OS(=O)(=O)C(F)(F)F)C3=C(C=C(C=C3)F)F Chemical compound C1=CC2=C(C=C1F)C(=O)N(N=C2OS(=O)(=O)C(F)(F)F)C3=C(C=C(C=C3)F)F GWHLZOPSGWEFMF-UHFFFAOYSA-N 0.000 description 5
- XSTDDDBFNOYBAK-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)Cl)OS(=O)(=O)C(F)(F)F Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)Cl)OS(=O)(=O)C(F)(F)F XSTDDDBFNOYBAK-UHFFFAOYSA-N 0.000 description 5
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- YSNXOQGDHGUKCZ-UHFFFAOYSA-N n-benzylhydroxylamine;hydron;chloride Chemical compound Cl.ONCC1=CC=CC=C1 YSNXOQGDHGUKCZ-UHFFFAOYSA-N 0.000 description 5
- NZEPWAXJSWYEDV-SECBINFHSA-N tert-butyl n-[(3r)-azepan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@@H]1CCCCNC1 NZEPWAXJSWYEDV-SECBINFHSA-N 0.000 description 5
- SQSWYWCEKCVQEA-UHFFFAOYSA-N (2-fluoro-5-formylphenyl)boronic acid Chemical compound OB(O)C1=CC(C=O)=CC=C1F SQSWYWCEKCVQEA-UHFFFAOYSA-N 0.000 description 4
- YGPHBSVMNUNGBH-UHFFFAOYSA-N (3-ethylsulfonylphenyl)boronic acid Chemical compound CCS(=O)(=O)C1=CC=CC(B(O)O)=C1 YGPHBSVMNUNGBH-UHFFFAOYSA-N 0.000 description 4
- YABSTJQEBSKPCG-UHFFFAOYSA-N (4-fluoro-3-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(C=O)=C1 YABSTJQEBSKPCG-UHFFFAOYSA-N 0.000 description 4
- DHXVJJHOVGTNDK-UHFFFAOYSA-N 4-bromo-2h-phthalazin-1-one Chemical compound C1=CC=C2C(Br)=NNC(=O)C2=C1 DHXVJJHOVGTNDK-UHFFFAOYSA-N 0.000 description 4
- MFMSHBHGIHTWMI-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=C(C=C3)F)Cl)Cl Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=C(C=C3)F)Cl)Cl MFMSHBHGIHTWMI-UHFFFAOYSA-N 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 4
- SGERXKCDWJPIOS-UHFFFAOYSA-N [3-(dimethylsulfamoyl)phenyl]boronic acid Chemical compound CN(C)S(=O)(=O)C1=CC=CC(B(O)O)=C1 SGERXKCDWJPIOS-UHFFFAOYSA-N 0.000 description 4
- VPQGUZSIKYKFNS-UHFFFAOYSA-N [3-(ethylsulfamoyl)phenyl]boronic acid Chemical compound CCNS(=O)(=O)C1=CC=CC(B(O)O)=C1 VPQGUZSIKYKFNS-UHFFFAOYSA-N 0.000 description 4
- 235000019270 ammonium chloride Nutrition 0.000 description 4
- WDWDWGRYHDPSDS-UHFFFAOYSA-N methanimine Chemical compound N=C WDWDWGRYHDPSDS-UHFFFAOYSA-N 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- NZEPWAXJSWYEDV-VIFPVBQESA-N tert-butyl n-[(3s)-azepan-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCCNC1 NZEPWAXJSWYEDV-VIFPVBQESA-N 0.000 description 4
- DGUWACLYDSWXRZ-UHFFFAOYSA-N (2-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1C=O DGUWACLYDSWXRZ-UHFFFAOYSA-N 0.000 description 3
- XPEIJWZLPWNNOK-UHFFFAOYSA-N (4-phenylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1=CC=CC=C1 XPEIJWZLPWNNOK-UHFFFAOYSA-N 0.000 description 3
- DEQOVKFWRPOPQP-UHFFFAOYSA-N (5-formylthiophen-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)S1 DEQOVKFWRPOPQP-UHFFFAOYSA-N 0.000 description 3
- VOIGKXSORJFLOX-UHFFFAOYSA-N 4-chloro-2-(4-methoxyphenyl)phthalazin-1-one Chemical compound COC1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C(=N2)Cl VOIGKXSORJFLOX-UHFFFAOYSA-N 0.000 description 3
- BGQXRLMOQYVVDC-UHFFFAOYSA-N C1=CC(=CC=C1N2C(=O)C3=C(C=NC=C3)C(=N2)OS(=O)(=O)C(F)(F)F)F Chemical compound C1=CC(=CC=C1N2C(=O)C3=C(C=NC=C3)C(=N2)OS(=O)(=O)C(F)(F)F)F BGQXRLMOQYVVDC-UHFFFAOYSA-N 0.000 description 3
- LFBBSVNDWYJJOZ-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=CC(=C3)F)F)Cl Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC(=CC(=C3)F)F)Cl LFBBSVNDWYJJOZ-UHFFFAOYSA-N 0.000 description 3
- ZHCDEFLRXFUAMA-UHFFFAOYSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)S(=O)(=O)N Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)S(=O)(=O)N ZHCDEFLRXFUAMA-UHFFFAOYSA-N 0.000 description 3
- POKZAWGJLOEGAK-UHFFFAOYSA-N CC(C)(C1CNCCN1)C(=O)OC Chemical compound CC(C)(C1CNCCN1)C(=O)OC POKZAWGJLOEGAK-UHFFFAOYSA-N 0.000 description 3
- YRJKTKCPKSAIST-UHFFFAOYSA-N CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F Chemical compound CCNS(=O)(=O)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=CC=C4F)F YRJKTKCPKSAIST-UHFFFAOYSA-N 0.000 description 3
- VKACPPJJAFXBBY-UHFFFAOYSA-N CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CC4=CC=CC=C4 Chemical compound CCS(=O)(=O)NC1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)CC4=CC=CC=C4 VKACPPJJAFXBBY-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 239000004472 Lysine Substances 0.000 description 3
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000012131 assay buffer Substances 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 3
- SQDFHQJTAWCFIB-UHFFFAOYSA-N n-methylidenehydroxylamine Chemical compound ON=C SQDFHQJTAWCFIB-UHFFFAOYSA-N 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- ABMYEXAYWZJVOV-UHFFFAOYSA-N pyridin-3-ylboronic acid Chemical compound OB(O)C1=CC=CN=C1 ABMYEXAYWZJVOV-UHFFFAOYSA-N 0.000 description 3
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- OAEJODVYVOAOPH-UHFFFAOYSA-N (2-fluoro-4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1F OAEJODVYVOAOPH-UHFFFAOYSA-N 0.000 description 2
- CSGAGFPHVVBHDF-UHFFFAOYSA-N (3-amino-4-chlorophenyl)boronic acid Chemical compound NC1=CC(B(O)O)=CC=C1Cl CSGAGFPHVVBHDF-UHFFFAOYSA-N 0.000 description 2
- XDBHWPLGGBLUHH-UHFFFAOYSA-N (3-cyanophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(C#N)=C1 XDBHWPLGGBLUHH-UHFFFAOYSA-N 0.000 description 2
- YJQDBKGGRPJSOI-UHFFFAOYSA-N (3-formyl-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1C=O YJQDBKGGRPJSOI-UHFFFAOYSA-N 0.000 description 2
- PMNJSWJJYWZLHU-UHFFFAOYSA-N (3-sulfamoylphenyl)boronic acid Chemical compound NS(=O)(=O)C1=CC=CC(B(O)O)=C1 PMNJSWJJYWZLHU-UHFFFAOYSA-N 0.000 description 2
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 2
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 2
- UTWMSGSDWZDPOM-UHFFFAOYSA-N 2-methyl-3-phenylcyclobutan-1-one Chemical compound C1C(=O)C(C)C1C1=CC=CC=C1 UTWMSGSDWZDPOM-UHFFFAOYSA-N 0.000 description 2
- QDIMUVCWIVIKLY-UHFFFAOYSA-N 3-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(3-methylphenyl)propanoic acid Chemical compound CC1=CC=CC(C(CC(O)=O)NC(=O)OCC2C3=CC=CC=C3C3=CC=CC=C32)=C1 QDIMUVCWIVIKLY-UHFFFAOYSA-N 0.000 description 2
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 2
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 2
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 2
- BPBKFUYKGPJBNO-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=C(C=C(C=C3)F)C(=O)N2 Chemical compound C1=CC=C(C=C1)N2C(=O)C3=C(C=C(C=C3)F)C(=O)N2 BPBKFUYKGPJBNO-UHFFFAOYSA-N 0.000 description 2
- HZNUIRRCSIJGOB-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3F)OS(=O)(=O)C(F)(F)F Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=CC=C3F)OS(=O)(=O)C(F)(F)F HZNUIRRCSIJGOB-UHFFFAOYSA-N 0.000 description 2
- IWGKXGCRXHDUTQ-UHFFFAOYSA-N C1CCC(C1)(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O Chemical compound C1CCC(C1)(C2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=C(C=C(C=C5)F)F)C(=O)O IWGKXGCRXHDUTQ-UHFFFAOYSA-N 0.000 description 2
- VWJQBNFVJSYVDJ-UHFFFAOYSA-N C1CCN(CC(C1)O)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound C1CCN(CC(C1)O)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F VWJQBNFVJSYVDJ-UHFFFAOYSA-N 0.000 description 2
- STMQSPBPUGSKJM-UHFFFAOYSA-N CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5=CC=CC=C5 Chemical compound CC(C)(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)NC5=CC=CC=C5 STMQSPBPUGSKJM-UHFFFAOYSA-N 0.000 description 2
- ORZVGQIVNIYEMT-YSMPRRRNSA-N CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=C3)=CC=C3F)C2=O)=CC=C1 Chemical compound CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=C3)=CC=C3F)C2=O)=CC=C1 ORZVGQIVNIYEMT-YSMPRRRNSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 2
- 108010077544 Chromatin Proteins 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- GISRWBROCYNDME-PELMWDNLSA-N F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C Chemical compound F[C@H]1[C@H]([C@H](NC1=O)COC1=NC=CC2=CC(=C(C=C12)OC)C(=O)N)C GISRWBROCYNDME-PELMWDNLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 description 2
- 210000003483 chromatin Anatomy 0.000 description 2
- NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- IZDROVVXIHRYMH-UHFFFAOYSA-N methanesulfonic anhydride Chemical compound CS(=O)(=O)OS(C)(=O)=O IZDROVVXIHRYMH-UHFFFAOYSA-N 0.000 description 2
- DCGAEWHBJDXIAZ-UHFFFAOYSA-N methyl n-chlorosulfonylcarbamate Chemical compound COC(=O)NS(Cl)(=O)=O DCGAEWHBJDXIAZ-UHFFFAOYSA-N 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical class [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108091035539 telomere Proteins 0.000 description 2
- 210000003411 telomere Anatomy 0.000 description 2
- 102000055501 telomere Human genes 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- RYGOBSYXIIUFOR-UHFFFAOYSA-N (1-methylpyrazol-4-yl)boronic acid Chemical compound CN1C=C(B(O)O)C=N1 RYGOBSYXIIUFOR-UHFFFAOYSA-N 0.000 description 1
- RSOSGLCEIHAGQV-UHFFFAOYSA-N (2,6-difluorophenyl)hydrazine;hydrochloride Chemical compound [Cl-].[NH3+]NC1=C(F)C=CC=C1F RSOSGLCEIHAGQV-UHFFFAOYSA-N 0.000 description 1
- QCSLIRFWJPOENV-UHFFFAOYSA-N (2-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC=C1F QCSLIRFWJPOENV-UHFFFAOYSA-N 0.000 description 1
- QWQBQRYFWNIDOC-UHFFFAOYSA-N (3,5-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC(F)=CC(F)=C1 QWQBQRYFWNIDOC-UHFFFAOYSA-N 0.000 description 1
- WJDZZXIDQYKVDG-UHFFFAOYSA-N (3-chloro-4-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(Cl)=C1 WJDZZXIDQYKVDG-UHFFFAOYSA-N 0.000 description 1
- KNXQDJCZSVHEIW-UHFFFAOYSA-N (3-fluorophenyl)boronic acid Chemical compound OB(O)C1=CC=CC(F)=C1 KNXQDJCZSVHEIW-UHFFFAOYSA-N 0.000 description 1
- ALTLCJHSJMGSLT-UHFFFAOYSA-N (3-methoxycarbonylphenyl)boronic acid Chemical compound COC(=O)C1=CC=CC(B(O)O)=C1 ALTLCJHSJMGSLT-UHFFFAOYSA-N 0.000 description 1
- RCRUXZHMXFQVRF-UHFFFAOYSA-N (3-pyrrolidin-1-ylsulfonylphenyl)boronic acid Chemical compound OB(O)C1=CC=CC(S(=O)(=O)N2CCCC2)=C1 RCRUXZHMXFQVRF-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- LQCCRPUZTXKDGB-UHFFFAOYSA-N (4-chloro-3-nitrophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C([N+]([O-])=O)=C1 LQCCRPUZTXKDGB-UHFFFAOYSA-N 0.000 description 1
- YNLGFXOBRXSMJZ-UHFFFAOYSA-N (4-cyclopropylphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1C1CC1 YNLGFXOBRXSMJZ-UHFFFAOYSA-N 0.000 description 1
- FEKUXLUOKFSMRO-UHFFFAOYSA-N (4-fluorophenyl)hydrazine;hydron;chloride Chemical compound Cl.NNC1=CC=C(F)C=C1 FEKUXLUOKFSMRO-UHFFFAOYSA-N 0.000 description 1
- VXWBQOJISHAKKM-UHFFFAOYSA-N (4-formylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)C=C1 VXWBQOJISHAKKM-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- OJOFMLDBXPDXLQ-SECBINFHSA-N (4r)-4-benzyl-1,3-oxazolidin-2-one Chemical compound C1OC(=O)N[C@@H]1CC1=CC=CC=C1 OJOFMLDBXPDXLQ-SECBINFHSA-N 0.000 description 1
- RKZHYRRFTYDWTH-UHFFFAOYSA-N (5-aminopyridin-3-yl)boronic acid Chemical compound NC1=CN=CC(B(O)O)=C1 RKZHYRRFTYDWTH-UHFFFAOYSA-N 0.000 description 1
- JUWYQISLQJRRNT-UHFFFAOYSA-N (5-formylfuran-2-yl)boronic acid Chemical compound OB(O)C1=CC=C(C=O)O1 JUWYQISLQJRRNT-UHFFFAOYSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical compound Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- NVNPLEPBDPJYRZ-UHFFFAOYSA-N 1-(bromomethyl)-4-fluorobenzene Chemical compound FC1=CC=C(CBr)C=C1 NVNPLEPBDPJYRZ-UHFFFAOYSA-N 0.000 description 1
- ZSKXYSCQDWAUCM-UHFFFAOYSA-N 1-(chloromethyl)-2-dodecylbenzene Chemical compound CCCCCCCCCCCCC1=CC=CC=C1CCl ZSKXYSCQDWAUCM-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- ABCXBNMWCHADNA-UHFFFAOYSA-N 1-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclopropane-1-carboxylic acid Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=CC(C2(CC2)C(O)=O)=C1 ABCXBNMWCHADNA-UHFFFAOYSA-N 0.000 description 1
- RLOHLPHAOHGRNM-UHFFFAOYSA-N 1-bromo-4-methylcyclohexane Chemical compound CC1CCC(Br)CC1 RLOHLPHAOHGRNM-UHFFFAOYSA-N 0.000 description 1
- PVISTSWZFOZJOI-UHFFFAOYSA-N 1-hydroxyazepane Chemical compound ON1CCCCCC1 PVISTSWZFOZJOI-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- XDXFUMZONWWODJ-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxyethanamine Chemical compound CC(C)(C)[Si](C)(C)OCCN XDXFUMZONWWODJ-UHFFFAOYSA-N 0.000 description 1
- GRWKNBPOGBTZMN-UHFFFAOYSA-N 2-benzyl-3-phenylpropane-1,2-diamine Chemical compound C=1C=CC=CC=1CC(N)(CN)CC1=CC=CC=C1 GRWKNBPOGBTZMN-UHFFFAOYSA-N 0.000 description 1
- BYUQIHOYADVGFD-UHFFFAOYSA-N 2-benzyl-4-chlorophthalazin-1-one Chemical compound O=C1C2=CC=CC=C2C(Cl)=NN1CC1=CC=CC=C1 BYUQIHOYADVGFD-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- HNWUEIWYUPQTKM-UHFFFAOYSA-N 2-methyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propanoic acid Chemical compound OC(=O)C(C)(C)C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 HNWUEIWYUPQTKM-UHFFFAOYSA-N 0.000 description 1
- WMPPDTMATNBGJN-UHFFFAOYSA-N 2-phenylethylbromide Chemical compound BrCCC1=CC=CC=C1 WMPPDTMATNBGJN-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- XTYYDYKRHLNSGN-UHFFFAOYSA-N 3-(4-methylphenyl)sulfonyloxetane Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1COC1 XTYYDYKRHLNSGN-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- XTJZBCBHCPQASK-UHFFFAOYSA-N 4,4-difluorocyclohexan-1-ol Chemical compound OC1CCC(F)(F)CC1 XTJZBCBHCPQASK-UHFFFAOYSA-N 0.000 description 1
- DQQNOFOIEBPHEQ-QGZVFWFLSA-N 4-[(3R)-3-[2-[tert-butyl(dimethyl)silyl]oxyethylamino]azepan-1-yl]-2H-phthalazin-1-one Chemical compound CC(C)(C)[Si](C)(C)OCCN[C@@H]1CCCCN(C1)C2=NNC(=O)C3=CC=CC=C32 DQQNOFOIEBPHEQ-QGZVFWFLSA-N 0.000 description 1
- YFCIFWOJYYFDQP-PTWZRHHISA-N 4-[3-amino-6-[(1S,3S,4S)-3-fluoro-4-hydroxycyclohexyl]pyrazin-2-yl]-N-[(1S)-1-(3-bromo-5-fluorophenyl)-2-(methylamino)ethyl]-2-fluorobenzamide Chemical compound CNC[C@@H](NC(=O)c1ccc(cc1F)-c1nc(cnc1N)[C@H]1CC[C@H](O)[C@@H](F)C1)c1cc(F)cc(Br)c1 YFCIFWOJYYFDQP-PTWZRHHISA-N 0.000 description 1
- RTEVQEDKZPFGNP-UHFFFAOYSA-N 4-bromo-1-methylpiperidine Chemical compound CN1CCC(Br)CC1 RTEVQEDKZPFGNP-UHFFFAOYSA-N 0.000 description 1
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 1
- JTRNQTFTRDPITG-UHFFFAOYSA-N 4-iodooxane Chemical compound IC1CCOCC1 JTRNQTFTRDPITG-UHFFFAOYSA-N 0.000 description 1
- TWWAWPHAOPTQEU-UHFFFAOYSA-N 4-methyl-2-benzofuran-1,3-dione Chemical compound CC1=CC=CC2=C1C(=O)OC2=O TWWAWPHAOPTQEU-UHFFFAOYSA-N 0.000 description 1
- XVMKZAAFVWXIII-UHFFFAOYSA-N 5-fluoro-2-benzofuran-1,3-dione Chemical compound FC1=CC=C2C(=O)OC(=O)C2=C1 XVMKZAAFVWXIII-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- QIEDECXMYBFMEN-UHFFFAOYSA-N C1=CC(=CC=C1N2C(=O)C3=C(C=NC=C3)C(=O)N2)F Chemical compound C1=CC(=CC=C1N2C(=O)C3=C(C=NC=C3)C(=O)N2)F QIEDECXMYBFMEN-UHFFFAOYSA-N 0.000 description 1
- ZHYVHVLOFOAZSE-UHFFFAOYSA-N C1=CC2=C(C=C1F)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)OS(=O)(=O)C(F)(F)F Chemical compound C1=CC2=C(C=C1F)C(=NN(C2=O)C3=C(C=C(C=C3)F)F)OS(=O)(=O)C(F)(F)F ZHYVHVLOFOAZSE-UHFFFAOYSA-N 0.000 description 1
- HUALEOKUDSVNDM-UHFFFAOYSA-N C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N Chemical compound C1=CC=C(C=C1)CN2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N HUALEOKUDSVNDM-UHFFFAOYSA-N 0.000 description 1
- MRTSAJOKAOCBQI-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=C(C=C(C=C3)F)C(=N2)Cl Chemical compound C1=CC=C(C=C1)N2C(=O)C3=C(C=C(C=C3)F)C(=N2)Cl MRTSAJOKAOCBQI-UHFFFAOYSA-N 0.000 description 1
- CFIWNZXXNVFSCK-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=C(C=CC(=C3)F)C(=N2)Cl Chemical compound C1=CC=C(C=C1)N2C(=O)C3=C(C=CC(=C3)F)C(=N2)Cl CFIWNZXXNVFSCK-UHFFFAOYSA-N 0.000 description 1
- NWBNSQSZSIPAIB-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=C(C=CC(=C3)F)C(=O)N2 Chemical compound C1=CC=C(C=C1)N2C(=O)C3=C(C=CC(=C3)F)C(=O)N2 NWBNSQSZSIPAIB-UHFFFAOYSA-N 0.000 description 1
- GMYNPUXDKUGDIU-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N Chemical compound C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N GMYNPUXDKUGDIU-UHFFFAOYSA-N 0.000 description 1
- UWHBIBQVTZXSDG-UHFFFAOYSA-N C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC=CC(=C4)C=O Chemical compound C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC=CC(=C4)C=O UWHBIBQVTZXSDG-UHFFFAOYSA-N 0.000 description 1
- QHDUDYGTDBOEFP-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)C(F)(F)F)C4=CC(=CC=C4)N Chemical compound C1=CC=C2C(=C1)C(=NN(C2=O)C3=CC=C(C=C3)C(F)(F)F)C4=CC(=CC=C4)N QHDUDYGTDBOEFP-UHFFFAOYSA-N 0.000 description 1
- GTUPLXZWRNUYEH-UHFFFAOYSA-N C1=CC=C2C(=C1)C(=O)NN(C2=O)C3=C(C=C(C=C3)F)F Chemical compound C1=CC=C2C(=C1)C(=O)NN(C2=O)C3=C(C=C(C=C3)F)F GTUPLXZWRNUYEH-UHFFFAOYSA-N 0.000 description 1
- KHBUTLGVDHCTSZ-UHFFFAOYSA-N C1CC(C1)N2C(=O)C3=CC=CC=C3C(=N2)Br Chemical compound C1CC(C1)N2C(=O)C3=CC=CC=C3C(=N2)Br KHBUTLGVDHCTSZ-UHFFFAOYSA-N 0.000 description 1
- PEEPIPWRPVECKL-UHFFFAOYSA-N C1CC1C2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C(=N3)Br Chemical compound C1CC1C2=CC=C(C=C2)N3C(=O)C4=CC=CC=C4C(=N3)Br PEEPIPWRPVECKL-UHFFFAOYSA-N 0.000 description 1
- NZTYBFCEDBEDSL-UHFFFAOYSA-N C1CC1CC(=O)NC2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl Chemical compound C1CC1CC(=O)NC2=CC=CC(=C2)C3=NN(C(=O)C4=CC=CC=C43)C5=CC=C(C=C5)Cl NZTYBFCEDBEDSL-UHFFFAOYSA-N 0.000 description 1
- NIUASIPMWPYXIN-UHFFFAOYSA-N C1CCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)Br Chemical compound C1CCC(C1)N2C(=O)C3=CC=CC=C3C(=N2)Br NIUASIPMWPYXIN-UHFFFAOYSA-N 0.000 description 1
- UBOCYIGZLUHGJF-UHFFFAOYSA-N C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N Chemical compound C1CCC(CC1)N2C(=O)C3=CC=CC=C3C(=N2)C4=CC(=CC=C4)N UBOCYIGZLUHGJF-UHFFFAOYSA-N 0.000 description 1
- YHAVBQKJTPNHJO-UHFFFAOYSA-N CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)N5CC(OC5=O)CC6=CC=CC=C6 Chemical compound CC(C)(C1CCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)N5CC(OC5=O)CC6=CC=CC=C6 YHAVBQKJTPNHJO-UHFFFAOYSA-N 0.000 description 1
- WAJMBURUEHCLAK-UHFFFAOYSA-N CC(C)(C1CN(CCN1C)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)OC Chemical compound CC(C)(C1CN(CCN1C)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F)C(=O)OC WAJMBURUEHCLAK-UHFFFAOYSA-N 0.000 description 1
- SRDKMKAFCGUKJX-UHFFFAOYSA-N CC(C)(C1CN(CCN1CC2=CC=CC=C2)CC3=CC=CC=C3)C(=O)OC Chemical compound CC(C)(C1CN(CCN1CC2=CC=CC=C2)CC3=CC=CC=C3)C(=O)OC SRDKMKAFCGUKJX-UHFFFAOYSA-N 0.000 description 1
- ZATRRNYSHCDRPB-UHFFFAOYSA-N CC(C)(CN)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound CC(C)(CN)C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F ZATRRNYSHCDRPB-UHFFFAOYSA-N 0.000 description 1
- FYCNUNMZHKWUBM-QQXSKIMKSA-N CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=C3)=CC=C3OC)C2=O)=CC=C1 Chemical compound CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=C3)=CC=C3OC)C2=O)=CC=C1 FYCNUNMZHKWUBM-QQXSKIMKSA-N 0.000 description 1
- VQGPUSAWZJOKOH-YSMPRRRNSA-N CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=CC=C3)=C3F)C2=O)=CC=C1 Chemical compound CC(C)/N=C\C1=CC(C(C2=CC=CC=C22)=NN(C(C=CC=C3)=C3F)C2=O)=CC=C1 VQGPUSAWZJOKOH-YSMPRRRNSA-N 0.000 description 1
- NPAFRTFFRVWDKY-YSMPRRRNSA-N CC(C)/N=C\C1=CC=CC=C1C(C1=CC=CC=C11)=NN(C(C=C2)=CC=C2F)C1=O Chemical compound CC(C)/N=C\C1=CC=CC=C1C(C1=CC=CC=C11)=NN(C(C=C2)=CC=C2F)C1=O NPAFRTFFRVWDKY-YSMPRRRNSA-N 0.000 description 1
- UNISHCPEJOCHRW-DICXZTSXSA-N CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] Chemical compound CC(C)/[N+](=C/C1=CC(=CC=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC(=CC=C4)F)/[O-] UNISHCPEJOCHRW-DICXZTSXSA-N 0.000 description 1
- SQAAQICMTMXGRD-UHFFFAOYSA-N CC1=C2C(=CC=C1)C(=O)N(N=C2OS(=O)(=O)C(F)(F)F)C3=CC=C(C=C3)F Chemical compound CC1=C2C(=CC=C1)C(=O)N(N=C2OS(=O)(=O)C(F)(F)F)C3=CC=C(C=C3)F SQAAQICMTMXGRD-UHFFFAOYSA-N 0.000 description 1
- QFESJHZRFGLFBN-UHFFFAOYSA-N CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)S(=O)(=O)C Chemical compound CN(C1=CC=CC(=C1)C2=NN(C(=O)C3=CC=CC=C32)C4=CC=CC=C4)S(=O)(=O)C QFESJHZRFGLFBN-UHFFFAOYSA-N 0.000 description 1
- WEXGOKFQYNQMLE-UHFFFAOYSA-N COC(=O)CC1CN(CCO1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F Chemical compound COC(=O)CC1CN(CCO1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F WEXGOKFQYNQMLE-UHFFFAOYSA-N 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000005971 DNA damage repair Effects 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 208000031448 Genomic Instability Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 1
- 101001046967 Homo sapiens Histone acetyltransferase KAT2A Proteins 0.000 description 1
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 1
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010025327 Lymphopenia Diseases 0.000 description 1
- 108010053229 Lysyl endopeptidase Proteins 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 101150051587 SIRT7 gene Proteins 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 102000000344 Sirtuin 1 Human genes 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- HSOUGLHWSPWPOM-UHFFFAOYSA-N [3-(2-hydroxyethylsulfamoyl)phenyl]boronic acid Chemical compound OCCNS(=O)(=O)C1=CC=CC(B(O)O)=C1 HSOUGLHWSPWPOM-UHFFFAOYSA-N 0.000 description 1
- ALMFIOZYDASRRC-UHFFFAOYSA-N [4-(trifluoromethyl)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(C(F)(F)F)C=C1 ALMFIOZYDASRRC-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N alpha-isobutyric acid Natural products CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- YKRBJQIVGGURGD-UHFFFAOYSA-N azepane-3-carbonitrile Chemical compound N#CC1CCCCNC1 YKRBJQIVGGURGD-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 1
- KXVUSQIDCZRUKF-UHFFFAOYSA-N bromocyclobutane Chemical compound BrC1CCC1 KXVUSQIDCZRUKF-UHFFFAOYSA-N 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 238000003381 deacetylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- KFOZNPPBKHYHQD-UHFFFAOYSA-N ethenesulfonyl chloride Chemical compound ClS(=O)(=O)C=C KFOZNPPBKHYHQD-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- YTJXGDYAEOTOCG-UHFFFAOYSA-N lithium;di(propan-2-yl)azanide;oxolane Chemical compound [Li+].C1CCOC1.CC(C)[N-]C(C)C YTJXGDYAEOTOCG-UHFFFAOYSA-N 0.000 description 1
- 231100001023 lymphopenia Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- RWIKCBHOVNDESJ-NSCUHMNNSA-N methyl (e)-4-bromobut-2-enoate Chemical compound COC(=O)\C=C\CBr RWIKCBHOVNDESJ-NSCUHMNNSA-N 0.000 description 1
- JIJJFPCPCIAIRE-UHFFFAOYSA-N methyl 1-(3-bromophenyl)cyclobutane-1-carboxylate Chemical compound C=1C=CC(Br)=CC=1C1(C(=O)OC)CCC1 JIJJFPCPCIAIRE-UHFFFAOYSA-N 0.000 description 1
- YVUPTHWIGCTHEW-UHFFFAOYSA-N methyl 1-piperidin-3-ylcyclopropane-1-carboxylate hydrochloride Chemical compound Cl.COC(=O)C1(CC1)C1CCCNC1 YVUPTHWIGCTHEW-UHFFFAOYSA-N 0.000 description 1
- JCQKPXHKGNJTQQ-UHFFFAOYSA-N methyl 2-(1,4-dibenzylpiperazin-2-yl)acetate Chemical compound C1CN(CC=2C=CC=CC=2)C(CC(=O)OC)CN1CC1=CC=CC=C1 JCQKPXHKGNJTQQ-UHFFFAOYSA-N 0.000 description 1
- PVCYXJXAUBLSJG-UHFFFAOYSA-N methyl 2-morpholin-2-ylacetate Chemical compound COC(=O)CC1CNCCO1 PVCYXJXAUBLSJG-UHFFFAOYSA-N 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- YKEKYBOBVREARV-UHFFFAOYSA-N pentanedioic acid Chemical compound OC(=O)CCCC(O)=O.OC(=O)CCCC(O)=O YKEKYBOBVREARV-UHFFFAOYSA-N 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 1
- ISYORFGKSZLPNW-UHFFFAOYSA-N propan-2-ylazanium;chloride Chemical compound [Cl-].CC(C)[NH3+] ISYORFGKSZLPNW-UHFFFAOYSA-N 0.000 description 1
- KPBSJEBFALFJTO-UHFFFAOYSA-N propane-1-sulfonyl chloride Chemical compound CCCS(Cl)(=O)=O KPBSJEBFALFJTO-UHFFFAOYSA-N 0.000 description 1
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WDPWEXWMQDRXAL-UHFFFAOYSA-N tert-butyl 1,4-diazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCNCC1 WDPWEXWMQDRXAL-UHFFFAOYSA-N 0.000 description 1
- VVDCRJGWILREQH-UHFFFAOYSA-N tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCC(B2OC(C)(C)C(C)(C)O2)=C1 VVDCRJGWILREQH-UHFFFAOYSA-N 0.000 description 1
- VAORLNIMLJVYKP-GOSISDBHSA-N tert-butyl N-[(3R)-1-[3-(2,4-difluorophenyl)-4-oxophthalazin-1-yl]azepan-3-yl]-N-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)[C@@H]1CCCCN(C1)C2=NN(C(=O)C3=CC=CC=C32)C4=C(C=C(C=C4)F)F VAORLNIMLJVYKP-GOSISDBHSA-N 0.000 description 1
- WUOQXNWMYLFAHT-QMMMGPOBSA-N tert-butyl n-[(3s)-piperidin-3-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H]1CCCNC1 WUOQXNWMYLFAHT-QMMMGPOBSA-N 0.000 description 1
- KVWAABHPICEOIE-UHFFFAOYSA-N tert-butyl n-[2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)C1=CC=CC(B2OC(C)(C)C(C)(C)O2)=C1 KVWAABHPICEOIE-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 1
- DQQJBEAXSOOCPG-UHFFFAOYSA-N tert-butyl n-pyrrolidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNC1 DQQJBEAXSOOCPG-UHFFFAOYSA-N 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the present invention relates to a phthalazine compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof; And it relates to a pharmaceutical composition for preventing or treating diseases related to Sirtuin 6 protein (hereinafter, referred to as'Sirt6') comprising the same as an active ingredient.
- Sirtuin proteins have been identified in a total of 7 species from Sirt1 to Sirt7, and most of them have been reported to be involved in aging, metabolic diseases, and gene stability.
- Sirt6 whole body Knock-out mice were normal at the stage of fetal development, but were smaller than the wild type after birth, and developed lymphopenia, osteopenia, abnormal metabolism, genomic instability, excessive inflammation, and myocardial hypertrophy.
- phenotypes such as growth retardation, fatty liver, cancer development, cirrhosis/inflammation, and decreased insulin secretion were observed (Proc. Natl. Acad. Sci. US A. 2010, 107, 21790-21794; Cell Metab.
- Sirt6 has functions of DNA damage repair, metabolic homeostasis (glucose metabolism and fat metabolism), inflammatory response control and lifespan-related mechanisms (Nature 2009, 460, 587-591). ). Sirt6 is partially present in the cytoplasmic stress granule and endoplasmic reticulum, but is mostly concentrated in the nucleus, especially chromatin, and is activated by NAD + cofactors (Sci. Rep. 2013, 3, 3085).
- H2K9, H3K56, H3K18 and etyltransferase GCN5 are known (Curr. Top. Med. Chem. 2013, 13, 2991-3000; Nature 2008, 452,492-496; Cell Cycle 2009, 8, and 2664-2666; Nat. Struct. Mol. Biol. 2016, 23, 434-440).
- H3K9 and H3K56, which are associated with the Sirt6 protein have been reported to regulate the transcriptional expression of certain genes and the stability of certain heterochromatins such as telomere by acetylation/deacetylation (Cell 2009, 136, 62-74; Cell, 2010.
- a compound having Sirt6 activity or a pharmaceutically acceptable salt thereof can be used for the treatment or prevention of diseases related to Sirt6 activity.
- Another object of the present invention is to provide a method for preparing a phthalazine compound, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof.
- Another object of the present invention is to provide a pharmaceutical composition for the prophylaxis or treatment of Sirt6-related diseases, including a phthalazine compound exhibiting sirt6 activity, or a racemate, stereoisomer or pharmaceutically acceptable salt thereof.
- Another object of the present invention is the prevention or treatment of Sirt6-related diseases comprising administering the phthalazine compound according to the present invention, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof to a subject in need thereof. It's about how to do it.
- Another object of the present invention is a phthalazine compound according to the present invention, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof; And it is to provide a pharmaceutical composition comprising at least one selected from the group consisting of a carrier, an excipient and a diluent.
- Means for solving the above problems in the present invention are as follows.
- X is CH or N
- R 1 is H, C 1-6 alkyl, or halo selected from the group consisting of fluoro, chloro and bromo,
- R 2 is selected from the group consisting of C 1-6 alkyl, aryl substituted C 1-6 alkyl, aryl, heteroaryl, C 3-7 cycloalkyl and heterocyclyl,
- R 3 is selected from the group consisting of aryl, heteroaryl and heterocyclyl
- the aryl, heteroaryl, cycloalkyl, and heterocyclyl may each be substituted with 1 to 3 substituents, and when these are substituted, the substituents are each independently selected from the group consisting of fluoro, chloro, and bromo.
- R 4 and R 5 are each a H, C 1-6 alkyl, one to three halogen atoms or a hydroxy C 1-6 alkyl, -SO 2 R 12 or -C (O) optionally substituted with R 15 independently,
- R 6 is C 1-6 alkyl or aryl substituted C 1-6 alkyl
- R 7 is C 1-6 alkyloxy or -NR 16 R 17 ,
- R 8 is C 1-6 alkyl or -NR 18 R 19 ,
- R 9 and R 10 are each independently H or C 1-6 alkyl, or R 9 and R 10 are bonded to each other to form a cycloalkyl together with the carbon atom to which they are attached,
- R 11 is cyano, amino, unsubstituted or amino substituted C 1-6 alkyl, unsubstituted or C 1-6 alkyl substituted heteroaryl, heterocyclyl, -CO 2 R 20 or -C(O)NR 20 R 21 ego,
- R 12 is C 1-6 alkyl, one to three halogen atoms substituted C 1-6 alkyl, C 3-6 cycloalkyl, or -NR 13 R 14,
- R 13 and R 14 are each independently H, C 1-6 alkyl or -CO 2 R 15 ,
- R 15 is -C 1-6 alkyl
- R 16 and R 17 are each independently H, heterocyclyloxy or hydroxy
- R 18 and R 19 are each independently H, unsubstituted or hydroxy substituted C 1-6 alkyl, or R 18 and R 19 are bonded to each other to form a heterocyclyl together with the N atom to which they are attached,
- R 20 is H or C 1-6 alkyl
- R 21 is H, unsubstituted or hydroxy substituted C 1-6 alkyl, cycloalkyl, aryl, or unsubstituted or C 1-6 alkyl substituted heteroaryl, or R 20 and R 21 are bonded to each other to form a heterocyclyl together with the N atom to which they are attached,
- the aryl is a C 6-10 aromatic ring group
- the cycloalkyl is a C 3-7 aliphatic cyclic group
- the heteroaryl is a 5-membered or 6-membered heteroaromatic ring group containing 1 to 4 hetero atoms selected from N, O and S in the ring,
- the heterocyclyl is a 4 to 7 membered heterocyclic group containing 1 to 2 hetero atoms selected from N and O in the ring.
- a pharmaceutical composition for the prophylaxis or treatment of Sirt6-related diseases comprising the compound represented by Formula 1, or a racemate, stereoisomer or pharmaceutically acceptable salt thereof.
- a novel phthalazine compound having excellent Sirt6 activity or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof has been provided. Since the compounds of the present invention, or racemates, stereoisomers, or pharmaceutically acceptable salts thereof, have been found to have excellent Sirt6 activity, they are expected to be useful in the prevention or treatment of Sirt6-related diseases.
- the present invention relates to a compound represented by the following formula (1), or a racemate, stereoisomer or pharmaceutically acceptable salt thereof:
- X is CH or N
- R 1 is H, C 1-6 alkyl, or halo selected from the group consisting of fluoro, chloro and bromo,
- R 2 is selected from the group consisting of C 1-6 alkyl, aryl substituted C 1-6 alkyl, aryl, heteroaryl, C 3-7 cycloalkyl and heterocyclyl,
- R 3 is selected from the group consisting of aryl, heteroaryl and heterocyclyl
- the aryl, heteroaryl, cycloalkyl and heterocyclyl may each be substituted with 1 to 3 substituents, and when these are substituted, the substituents are each independently selected from the group consisting of fluoro, chloro, and bromo.
- R 4 and R 5 are each a H, C 1-6 alkyl, one to three halogen atoms or a hydroxy C 1-6 alkyl, -SO 2 R 12 or -C (O) optionally substituted with R 15 independently,
- R 6 is C 1-6 alkyl or aryl substituted C 1-6 alkyl
- R 7 is C 1-6 alkyloxy or -NR 16 R 17 ,
- R 8 is C 1-6 alkyl or -NR 18 R 19 ,
- R 9 and R 10 are each independently H or C 1-6 alkyl, or R 9 and R 10 are bonded to each other to form a cycloalkyl together with the carbon atom to which they are attached,
- R 11 is cyano, amino, unsubstituted or amino substituted C 1-6 alkyl, unsubstituted or C 1-6 alkyl substituted heteroaryl, heterocyclyl, -CO 2 R 20 or -C(O)NR 20 R 21 ego,
- R 12 is C 1-6 alkyl, one to three halogen atoms substituted C 1-6 alkyl, C 3-6 cycloalkyl, or -NR 13 R 14,
- R 13 and R 14 are each independently H, C 1-6 alkyl or -CO 2 R 15 ,
- R 15 is -C 1-6 alkyl
- R 16 and R 17 are each independently H, heterocyclyloxy or hydroxy
- R 18 and R 19 are each independently H, unsubstituted or hydroxy substituted C 1-6 alkyl, or R 18 and R 19 are bonded to each other to form a heterocyclyl together with the N atom to which they are attached,
- R 20 is H or C 1-6 alkyl
- R 21 is H, unsubstituted or hydroxy substituted C 1-6 alkyl, cycloalkyl, aryl, or unsubstituted or C 1-6 alkyl substituted heteroaryl, or R 20 and R 21 are bonded to each other to form a heterocyclyl together with the N atom to which they are attached,
- the aryl is a C 6-10 aromatic ring group
- the cycloalkyl is a C 3-7 aliphatic cyclic group
- the heteroaryl is a 5- or 6-membered heteroaromatic ring group containing 1 to 4 hetero atoms selected from N, O and S in the ring,
- the heterocyclyl is a 4 to 7 membered heterocyclic group containing 1 to 2 heteroatoms selected from N and O in the ring, and these may optionally contain 1-2 double bonds in the ring. You may.
- R 2 is C 1-6 alkyl; C 1-6 alkyl substituted with C 6-10 aryl; Unsubstituted C 6-10 aryl; C 6-10 aryl substituted with 1 to 2 substituents selected from the group consisting of C 1-6 alkyl, fluoro substituted C 1-6 alkyl, C 1-6 alkyloxy, fluoro, chloro and bromo; Unsubstituted C 3-7 cycloalkyl; C 3-7 cycloalkyl substituted with 1 to 2 substituents selected from the group consisting of fluoro, chloro, bromo and C 1-6 alkyl; Unsubstituted heteroaryl; Or heteroaryl substituted with C 1-6 alkyl.
- R 3 is halo selected from the group consisting of fluoro, chloro and bromo, nitro, cyano, unsubstituted or C 1-6 substituted with 1 to 3 halogen atoms.
- R 3 is -NR 4 R 5
- It may be an aryl further substituted with a substituent selected from the group consisting of R 11 .
- R 3 is aryl further substituted with a substituent -NR 4 R 5
- R 4 is H, C 1-6 alkyl or C 1-6 alkylsulfonyl
- R 5 is H, unsubstituted or hydroxy substituted C 1-6 alkyl, -C(O)R 15 or -SO 2 R 12
- R 12 is C 1-6 alkyl, fluoro substituted C 1-6 alkyl, C 3-6 cycloalkyl or -NR 13 R 14
- R 13 and R 14 are each independently H, C 1-6 alkyl or -CO 2 R 15
- R 15 is -C 1-6 alkyl.
- the substituents R 3 -CH N + (O -) if the further substituted aryl as R 6, R 6 is C 1-6 alkyl or aryl-substituted C 1- 6 is alkyl.
- R 3 when R 3 is aryl further substituted with a substituent -C(O)R 7 , R 7 is -NR 16 R 17 , R 16 is H, and R 17 Is H, heterocyclyloxy or hydroxy.
- R 3 is aryl further substituted with a substituent -SO 2 R 8
- R 8 is -NR 18 R 19
- R 18 is H or C 1-6 alkyl
- R 19 is H, C 1-6 alkyl or hydroxy substituted C 1-6 alkyl, or R 18 and R 19 may be bonded to each other to form a heterocyclyl together with the N atom to which they are attached.
- R 9 and R 10 are each H or C 1-6 alkyl, or R 9 and R 10 may be bonded to each other to form a cycloalkyl together with the carbon atom to which they are attached, and R 11 is cyano, amino, unsubstituted or C 1-6 alkyl substituted heteroaryl, heterocyclyl, -CO 2 R 20 or -C(O)NR 20 R 21 , wherein R 20 is H or C 1-6 alkyl, and R 21 is H, unsubstituted or hydroxy substituted C 1-6 alkyl, cycloalkyl, aryl, or Unsubstituted or C 1-6 alkyl substituted heteroaryl, or R 20 and R 21 may be bonded to each other to form a heterocyclyl together with the N atom to which they are attached.
- the aryl is phenyl or naphthyl.
- the heteroaryl is pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, oxazolyl, thienyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, Oxadiazolyl, furanyl, thiophenyl, pyridinyl, pyridazinyl, pyrimidyl, triazinyl, pyrazinyl and pyridine-N-oxide.
- the heterocyclyl is tetrahydropyranyl, tetrahydrofuranyl, dihydrofuranyl, dihydropyranyl, tetrahydropyridinyl, dioxanyl, ditianyl, diox. It is selected from the group consisting of solanyl, imidazolidinyl, imidazolinyl, pyrrolinyl, piperazinyl, morpholinyl, thiomorpholinyl, piperidinyl, oxetanyl, pyrrolidinyl and azepanyl .
- the compound of Formula 1 of the present invention may exist in the form of a pharmaceutically acceptable salt.
- Examples of pharmaceutically acceptable salts include acid addition salts formed by pharmaceutically acceptable free acids.
- pharmaceutically acceptable salt refers to an acid addition salt of the compound in which the side effects caused by the salt at a concentration that is relatively non-toxic and harmless to the patient do not degrade the efficacy of the compound represented by Formula 1 As such, the acid may be both an organic acid and an inorganic acid.
- inorganic acids include, but are not limited to, hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, and the like
- organic acids include methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, Oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid, citric acid, lactic acid, glycolic acid, gluconic acid, galactu Ronic acid, glutamic acid, glutaric acid (glutaric acid), glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, and the like, but are not limited thereto.
- a pharmaceutically acceptable salt may be a metal salt prepared using a base.
- the metal salt include, but are not limited to, sodium salt, potassium salt, or calcium salt.
- the metal salt may be provided in the form of a silver salt obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (eg, silver nitrate).
- salts are only exemplary, and the salt of the compound of Formula 1 is a pharmaceutically acceptable salt, and any salt exhibiting the same level of Sirt6 activity as the compound of Formula 1 may be used without limitation.
- the present invention is a pharmaceutical composition for the prophylaxis or treatment of Sirt6-related diseases comprising the compound of Formula 1, or a racemate, stereoisomer or pharmaceutically acceptable salt thereof, and a compound of Formula 1, or a racemic thereof It relates to a method of treating Sirt6 related diseases using a sieve, stereoisomer or a pharmaceutically acceptable salt.
- the compound of Formula 1 of the present invention exhibits Sirt6 activity, and thus may be usefully used in the prevention or treatment of Sirt6-related diseases.
- the Sirt6-related diseases may include cancer, fatty liver, cirrhosis/inflammation of the liver, low insulin secretion, diseases caused by aging, but are not limited to specific diseases, and include all diseases known to be related to Sirt6 activity. do.
- prevention refers to all actions that inhibit or delay the occurrence, spread, and recurrence of Sirt6 related diseases by administration of the composition of the present invention
- treatment It refers to any action in which the symptoms of the disease are improved or beneficially changed by administration .
- the present invention comprises administering a compound represented by Formula 1, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof to a subject in need thereof. It relates to a method of preventing or treating.
- the pharmaceutical composition of the present invention in addition to the compound of Formula 1, or a racemate, stereoisomer or pharmaceutically acceptable salt thereof, as an active ingredient, as an active ingredient, for the prevention or treatment of each disease, depending on the type of disease to be prevented or treated. It may further include a known drug used for. For example, when used for the prophylaxis or treatment of Sirt6-related diseases, in addition to the compound of Formula 1, or a racemate, stereoisomer, or pharmaceutically acceptable salt thereof as an active ingredient, known additives commonly used in the field of the present invention , for example, it may further include any one of a pharmaceutically acceptable carrier, excipient, and diluent, and may be used in combination with other known treatments for the treatment of the disease. Other treatments include, but are not limited to, chemotherapy, radiation therapy, hormone therapy, bone marrow transplantation, stem-cell replacement therapy, other biological therapy, immunotherapy, and the like.
- Step 1 Phthalic anhydride (5 g, 33.76 mmol) and 2,4-difluorophenylhydrazine hydrochloride (6.70 g, 37.13 mmol) were added to acetic acid (50 mL), followed by stirring at 120° C. for 24 hours. The reaction solution was cooled to room temperature, 100 mL of purified water was added, stirred for 1 hour, and the precipitated solid was filtered. The obtained solid and NaOH (2.02 g, 50.63 mmol) were diluted in EtOH and then stirred at 40° C. for 1 hour or more. The reaction solution was concentrated under reduced pressure, diluted in purified water, and adjusted to pH 5-6 using 1N HCl. The precipitated crystals were stirred for at least 10 minutes and then filtered to obtain 5.1 g of 2-(2,4-difluorophenyl)-2,3-dihydrophthalazine-1,4-dione.
- Step 2 DCM (250 mL) and trimethylamine (3.05 mL, 21.88 mmol) were added to the compound obtained from step 1 (2.50 g, 9.12 mmol), followed by cooling with an ice-salt bath, and trifluoromethanesulfonic anhydride After dropping (2.30 mL, 13.68 mmol), the mixture was stirred at room temperature for 2 hours.
- the reaction product was diluted with DCM, washed with 2N HCl, and the organic layer was extracted. The separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 1.91 g of the title compound.
- Phthalic anhydride (5.00 g, 33.76 mmol) and 2,6-difluorophenylhydrazine hydrochloride (6.70 g, 37.13 mmol) were reacted in the same manner as in Preparation Example 2-1 to obtain 1.70 g of the title compound.
- Step 1 Phenylhydrazine hydrochloride (13 g, 90.36 mmol) and 10% HCl (400 mL) were added to 4-fluorophthalic anhydride (10 g, 60.24 mmol), followed by stirring at 110° C. for 24 hours. After confirming the reaction product by TLC, the reaction solution was diluted with EtOAc and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography.
- Step 2 Intermediate compounds 6-fluoro-2-phenyl-2,3-dihydrophthalazine-1,4-dione and 7-fluoro-2-phenyl-2,3-dihydro obtained from step 1 Phosphoryl chloride (25 mL) was added to loftalazine-1,4-dione (1.07 g, 4.17 mmol), followed by stirring at 120° C. for 2 hours. After cooling the reaction product to room temperature, the excess solvent was distilled off, and the resulting solid was recovered by placing it in ice water. The solid obtained by filtration was dissolved in DCM, neutralized by adding saturated NaHCO 3 aqueous solution, and extracted with DCM. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 550 mg of compound I-11 and 428 mg of compound I-12.
- Step 1 Puro[3,4-c]pyridin-1,3-dione (200 mg, 1.341 mmol) and (4-fluorophenyl) hydrazine hydrochloride (262 mg, 1.61 mmol) were added to acetic acid (2 mL). After dilution, the mixture was stirred at 120° C. for 15 hours. After cooling the reaction solution between 0 and 5°C, purified water was added, stirred for 30 minutes, and the precipitated solid was filtered. The obtained solid and NaOH (80 mg, 2.011 mmol) were diluted in EtOH and then stirred at 40° C. for 1 hour or more.
- reaction solution was concentrated under reduced pressure, diluted in purified water, and adjusted to pH 6 using 1N HCl.
- the precipitated crystals were stirred for at least 10 minutes and then filtered to obtain 260 mg of 2-(4-fluorophenyl)-2,3-dihydropyrido[3,4-d]pyridazin-1,4-dione. .
- Step 2 The compound obtained from Step 1 (200 mg, 0.778 mmol) and TEA (217 ⁇ L 1.555 mmol) were diluted in 5 mL of DCM and then cooled between -10 and -5 °C. Trifluoromethanesulfonic anhydride (158 ⁇ L, 0.933 mmol) was diluted in 1 mL of DCM, added dropwise to the reaction solution for 10 minutes, and stirred for 1 hour while gradually raising the temperature to room temperature. The reaction solution was diluted with an aqueous ammonium chloride solution and DCM, and the organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 64 mg of the title compound.
- Trifluoromethanesulfonic anhydride 158 ⁇ L, 0.933 mmol
- Step 1 Dibenzylethylenediamine (1.61 g, 6.70 mmol), methyl (E)-4-bromobut-2-enoate (1.00 g, 6.00 mmol) and Et 3 N (2.8 ml, 16.75 mmol) were anhydrous. After dissolving toluene (20 ml), the mixture was stirred at room temperature for 48 hours. The reaction product was diluted with EtOAc, washed with a saturated aqueous NaHCO 3 solution, and the organic layer was extracted. The separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 1.1 g of methyl 2-(1,4-dibenzylpiperazin-2-yl)acetate.
- Step 2 The compound obtained from Step 1 (1.00 g, 2.96 mmol) was dissolved in anhydrous THF (20 ml), and then cooled to -78°C. 2M LDA-THF (5.9 ml, 11.80 mmol) was slowly added and stirred at -30°C for 1 hour. After re-cooling the reaction solution to -78 °C, iodomethane (0.55 ml, 8.86 mmol) and HMPA (10 ⁇ l, 0.06 mmol) were added. The reaction mixture was slowly raised to 0° C. and then stirred at room temperature for 5 hours. The reaction product was diluted with EtOAc, washed with saturated NaHCO 3 aqueous solution, and the organic layer was extracted.
- Step 3 After dissolving the compound (260 mg, 0.71 mmol) obtained from step 2 in anhydrous MeOH (10 ml), Pd/C (38 mg) and Pd(OH) 2 were added, followed by stirring at room temperature for 4 hours. The reaction bath solution was filtered using Celite Pad, washed with MeOH, and then the organic solvent was concentrated under reduced pressure to remove. Separation by column chromatography gave 125 mg of the title compound.
- Step 1 Compound I-1 (500 mg, 1.95 mmol), 3-aminophenylboronic acid (293 mg, 2.14 mmol), Pd(OAc) 2 (13 mg, 0.06 mmol) and sSPhos (60 mg, 0.12 mmol) was added to 1,4-dioxane/distilled water (14 mL, 1:1 ratio) and stirred at 100° C. for 5 hours.
- the reaction product was diluted with EtOAc and washed with purified water.
- the separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 412 mg of 4-(3-aminophenyl)-2-phenylphthalazine-1(2H)-one.
- Step 2 Pyridine (10 mL) was added to the compound (200 mg, 0.63 mmol) obtained from step 1, ethanesulfonyl chloride (73 ⁇ L, 0.76 mmol) was added dropwise, followed by stirring at room temperature for 5 hours. The reaction was diluted with EtOAc and washed with purified water. The separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 122 mg of the title compound.
- compound I-3 (500 mg, 1.54 mmol) was used and reacted in the same manner as in Step 1 of Example 1 to obtain 408 mg of the title compound as a white solid.
- Example 2 The compound of Example 2 (100 mg, 0.26 mmol) was reacted in the same manner as in Step 2 of Example 1 to obtain 78 mg of the title compound.
- Example 2 The compound of Example 2 (100 mg, 0.26 mmol), acetaldehyde (24 ⁇ L, 0.40 mmol) and 8M borane-pyridine complex (50 ⁇ L, 0.40 mmol) were dissolved in MeOH (7 mL) at room temperature in the presence of 4 ⁇ molecular sieves. Reacted for 24 hours. The reaction solution was filtered using Celite Pad, washed with MeOH, and the organic solvent was concentrated under reduced pressure and then separated by column chromatography to obtain 45 mg of the title compound as a white solid.
- Example 6 The compound of Example 6 (20 mg, 0.05 mmol) was reacted in the same manner as in Example 5 to obtain 21 mg of the title compound.
- Step 1 Compound I-2 (500 mg, 1.83 mmol) and 3-aminophenylboronic acid (375 mg, 2.74 mmol) were reacted in the same manner as in Step 1 of Example 1 to obtain 440 mg of 4-(3-amino). Phenyl)-2-(4-fluorophenyl)phthalazine-1(2H)-one was obtained.
- Step 2 The compound obtained from Step 1 (100 mg, 0.30 mmol) and methanesulfonic anhydride (68 ⁇ L, 0.36 mmol) were reacted in the same manner as in Step 2 of Example 1 to obtain 78 mg of the title compound.
- Step 1 Compound I-1 (1 g, 3.02 mmol), 3-formylphenylboronic acid (543 mg, 3.62 mmol) and Pd(PPh 3 ) 4 (104 mg, 0.09 mmol) were added to 1,4-dioxane ( 50 mL), Na 2 CO 3 (1.5 g, 14.48 mmol) was dissolved in H 2 O (15 mL) and added together, followed by stirring at 110° C. for 2 hours.
- reaction product was diluted with EtOAc and washed with purified water, and the separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 1.2 g of 3-(4-oxo-3-phenyl-3,4 -Dihydrophthalazin-1-yl)benzaldehyde was obtained.
- Step 2 The compound obtained from Step 1 (100 mg, 0.31 mmol) was dissolved in anhydrous EtOH (5 mL), and N-methylhydroxylamine hydrochloride (128 mg, 1.53 mmol), potassium acetate (150 mg, 1.53 mmol) After addition, the mixture was stirred at room temperature for 48 hours. After the solvent was concentrated to remove EtOH, it was diluted with EtOAc and washed with purified water. The separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 45 mg of the title compound.
- Example 24 The compound obtained in Example 24 (50 mg, 0.14 mmol) and ethanesulfonyl chloride (16 ⁇ L, 0.17 mmol) were reacted in the same manner as in Step 2 of Example 1 to obtain 33 mg of the title compound as a white solid. .
- Example 24 The compound of Example 24 (100 mg, 0.28 mmol) and methyl (chlorosulfonyl) carbamate (57 mg, 0.33 mmol) were reacted in the same manner as in Step 2 of Example 1 to obtain 71 mg of the title compound as a white solid. Obtained.
- Example 48 (Z)-1-(5-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)furan-2-yl)-N -Isopropylmethanimine oxide
- Step 1 After dissolving 4-chlorophthalazine-1(2H)-one (200 mg, 1.10 mmol) in DMF (10 mL), it was cooled to 0 °C. NaH (50 mg, 1.3 mmol) was added and stirred at 0 °C for 10 minutes, and then benzyl bromide (145 ⁇ L, 1.20 mmol) was slowly added. After the reaction was reacted at room temperature for 2 hours, the completion of the reaction was confirmed by TLC. The reaction solution was diluted with EtOAc and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 170 mg of 2-benzyl-4-chlorophthalazine-1(2H)-one.
- Step 2 After dissolving the compound (100 mg, 0.37 mmol) obtained in step 1 in dioxane (5 mL), Pd(dppf)Cl 2 (27 mg, 10 mol%), (3-aminophenyl) boronic acid ( 56 mg, 0.40 mmol), K 3 PO 4 (235 mg, 1.10 mmol) and sSPhos (19 mg, 10 mol%) were added. After the reaction was stirred at 100° C. for 8 hours, the reaction solution was diluted with EtOAc and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 83 mg of 4-(3-aminophenyl)-2-benzylphthalazine-1(2H)-one.
- Step 3 The compound obtained in Step 2 (50 mg, 0.15 mmol) was reacted in the same manner as in Step 2 of Example 1 to obtain 34 mg of the title compound.
- Example 64 Using the compound of Example 64 (60 mg, 0.10 mmol) as a starting material and reacting in the same manner as in Example 5, 59 mg of the title compound was obtained.
- Example 10 Using the compound of Example 10 (60 mg, 0.15 mmol) as a starting material and reacting in the same manner as in Example 5, 56 mg of the title compound was obtained.
- Example 70 N-(3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl) phenyl)-N-methylethanesulfonamide
- Example 11 Using the compound of Example 11 (60 mg, 0.14 mmol) as a starting material and reacting in the same manner as in Example 5, 51 mg of the title compound was obtained.
- Example 68 The compound of Example 68 (30 mg, 0.07 mmol) was used as a starting material and reacted in the same manner as in Example 5 to obtain 26 mg of the title compound.
- Example 67 Using the compound of Example 67 (30 mg, 0.07 mmol) as a starting material, it was reacted in the same manner as in Example 5 to obtain 25 mg of the title compound.
- Example 71 Using the compound of Example 71 (30 mg, 0.07 mmol) as a starting material, it was reacted in the same manner as in Example 5 to obtain 20 mg of the title compound.
- Example 12 Using the compound of Example 12 (30 mg, 0.07 mmol) as a starting material and reacting in the same manner as in Example 5, 23 mg of the title compound was obtained.
- Example 76 Methyl (N-(3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)-N-methylsulfamoyl)( Methyl) carbamate
- Example 20 Using the compound of Example 20 (150 mg, 0.32 mmol) as a starting material and reacting in the same manner as in Example 5, 117 mg of the title compound was obtained.
- Example 78 1,1,1-trifluoro-N-(3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl) -N-methylmethanesulfonamide
- Example 77 Using the compound of Example 77 (30 mg, 0.07 mmol) as a starting material, it was reacted in the same manner as in Example 5 to obtain 17 mg of the title compound.
- Step 1 After dissolving the compound of Example 66 (750 mg, 2.00 mmol) in THF/MeOH/H 2 O (100 mL, 3:1:1 ratio), LiOH-H 2 O (420 mg, 10.02 mmol) was added. And stirred at room temperature for 3 hours. The reactant concentrated under reduced pressure was diluted with EtOAc, washed with 1N HCl aqueous solution, and then dehydrated with anhydrous Na 2 SO 4 to give 667 mg of 3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydro. Loftalazin-1-yl)benzoic acid was obtained.
- Step 2 After dissolving the compound (150 mg, 0.42 mmol) obtained from step 1 in DCM (4 mL), DIPEA (0.7 mL, 4.16 mmol), EDCI (159 mg, 0.83 mmol), HOBt (84 mg, 0.62) mmol) was added and stirred at room temperature for 12 hours. The reaction was concentrated under reduced pressure, diluted with EtOAc, and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 144 mg of the title compound as a white solid.
- Example 80 N-(3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl) phenyl)-N-methyl-methylsulfamoylamide
- Example 81 4-(3-(1H-tetrazol-5-yl)phenyl)-2-(4-fluorophenyl)phthalazine-1(2H)-one
- Step 1 Compound I-2 (200 mg, 0.72 mmol) and 3-cyanophenylboronic acid (127 mg, 0.86 mmol) were reacted in the same manner as in Step 1 of Example 1 to obtain 214 mg of 3-(3- (4-Fluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)benzonitrile was obtained.
- Step 2 Add the compound obtained from step 1 (100 mg, 0.29 mmol), NaN 3 (23 mg, 0.35 mmol) and NH 4 Cl (19 mg, 0.35 mmol) in DMF (5 mL), and 12 at 120 °C Stirred for hours. 0.5N HCl aqueous solution was added to adjust the pH of the reaction solution to 5-6, and the resulting crystals were filtered to obtain 24 mg of the title compound.
- Example 82 N-(5-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl) pyridin-3-yl)ethanesulfonamide
- N-isopropylhydroxylamine hydrochloride was used instead of N-ethylhydroxylamine hydrochloride, and [1,1'-biphenyl]-4-ylboronic acid (100 mg, 0.50 mmol) was used instead of 3-formylphenylboronic acid. Then, by reacting in the same manner as in Example 16, 24 mg of the title compound was obtained.
- Example 102 (Z)-1-(3-(3-(2,6-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-N- Methylmethanimine oxide
- Example 103 (Z)-1-(3-(3-(2,6-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-N- Isopropylmethanimine oxide
- Example 104 (Z)-N-tert-butyl-1-(3-(3-(2,6-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl )Phenyl)methanimine oxide
- Example 106 2-(2,6-difluorophenyl)-4-(3-(ethylsulfonyl)phenyl)phthalazine-1(2H)-one
- Step 1 Compound I-2 (173 mg, 0.63 mmol) and 3-pyridinylboronic acid (141 mg, 0.94 mmol) were reacted in the same manner as in Step 1 of Example 1 to obtain 94 mg of 2-(4-fluoro). Lophenyl)-4-(pyridin-3-yl)phthalazine-1(2H)-one was obtained.
- Step 2 After dissolving the compound (74 mg, 0.26 mmol) obtained from step 1 in DCM (40 mL), mCPBA (136 mg, 0.79 mmol) was added, followed by stirring at room temperature for 4 hours. The reaction solution was diluted with EtOAc, washed with purified water, and the organic layer was dehydrated with anhydrous Na 2 SO 4 and then separated by column chromatography to obtain 46 mg of the title compound.
- Example 115 The compound of Example 115 (70 mg, 0.21 mmol) was reacted in the same manner as in Step 2 of Example 114 to obtain 60 mg of the title compound.
- Example 116 The compound of Example 116 (70 mg, 0.21 mmol) was reacted in the same manner as in Step 2 of Example 114 to obtain 54 mg of the title compound.
- Example 120 2-(2,4-difluorophenyl)-7-fluoro-4-(3-(methylsulfonyl)phenyl) phthalazine-1(2H)-one
- Example 127 3-(3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)-N-(2-hydroxyethyl)benzenesulfone amides
- Example 128 N-(3-(3-cyclohexyl-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl) ethanesulfonamide
- Step 1 After diluting 4-bromophthalazine-1(2H)-one (300 mg, 1.333 mmol) and K 2 CO 3 (368 mg, 2.67 mmol) in DMF (4.4 mL), bromocyclohexane ( 326 mg, 2.00 mmol) was added and stirred at 100° C. for 24 hours. The reaction solution was cooled to room temperature, diluted with EA, and washed with purified water. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 108.7 mg of 4-bromo-2-cyclohexylphthalazine-1(2H)-one as a white solid.
- Step 2 The compound obtained from Step 1 (105 mg, 0.342 mmol) and (3-aminophenyl) boronic acid (51.5 mg, 0.376 mmol) were reacted in the same manner as in Step 1 of Example 1 to obtain 60.1 mg as a white solid. Of 4-(3-aminophenyl)-2-cyclohexylphthalazine-1(2H)-one was obtained.
- Step 3 The compound obtained from step 2 (32 mg, 0.100 mmol) was dissolved in pyridine, cooled to 0 to 5 °C, ethanesulfonyl chloride (11.39 ⁇ L, 0.120 mmol) was added dropwise for 5 minutes, and then at room temperature for 2 hours While stirring. The reaction solution was diluted with EA and washed 4-5 times with saturated CuSO 4 aqueous solution. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 31.3 mg of the title compound as a white solid.
- Example 130 The compound of Example 130 (20 mg, 0.059 mmol), hydroxylamine hydrochloride (4.89 mg, 0.070 mmol), and NaHCO 3 (7.38 mg, 0.088 mmol) were dissolved in EtOH (585 ⁇ L) and stirred at 80° C. for 3 hours. I did. After cooling the reaction solution to room temperature, water was added to the precipitated solid was filtered and washed with distilled water. The filtered solid was crystallized using DCM and MeOH and dried to give 6.4 mg of the title compound as a white solid.
- Example 132 N-(3-(3-isopropyl-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl) ethanesulfonamide
- Step 1 Compound I-2 (70 mg, 0.219 mmol) and tert -butyl piperidin-3-ylcarbamate (52.7 mg, 0.263 mmol), XPhos (90 mg, 0.940 mmol) and NaOtBu (90 mg, 0.940 mmol) was diluted in toluene (1.04 mL), and then Pd 2 (dba) 3 was added, followed by reaction in a microwave reactor at 120° C. for 1 hour. The reaction solution was cooled to room temperature, diluted with EA, and washed with purified water.
- Step 2 After dissolving the compound (50 mg, 0.114 mmol) obtained from step 1 in DCM (380 ⁇ L), 4M HCl dioxane solution (855 ⁇ L) was slowly added at 0° C. and stirred at room temperature for 2 hours. After the reaction mixture was concentrated, the precipitated solid was filtered, washed with ether, and dried to give 43 mg of the title compound as a pale yellow solid.
- Example 134 The compound of Example 134 (20 mg, 0.053 mmol) was reacted in the same manner as in Step 3 of Example 128 to obtain 5.5 mg of the title compound as a white solid.
- Example 140 N-(3-(3-(4,4-difluorocyclohexyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)ethanesulfonamide
- Step 1 4-bromophthalazine-1 (2H)-one (50 mg, 0.222 mmol) and 4,4-difluorocyclohexan-1-ol (36.6 mg, 0.267 mmol) in THF (741 ⁇ L) After dissolving in, PPh 3 (87 mg, 0.333 mmol) and DIAD (67.4 mg, 0.333 mmol) were added at 0 °C, followed by stirring at room temperature for 1 hour. The reaction solution was diluted with EA and washed with purified water.
- Step 2 The compound obtained from Step 1 (150 mg, 0.437 mmol) was reacted in the same manner as in Steps 2 and 3 of Example 128 to obtain 18.6 mg of the title compound as a pale ocher solid.
- Example 141 N-(1-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazine- 1-yl)azepan-3-yl)ethanesulfonamide
- Example 134 4-bromo-2-cyclohexylphthalazine-1(2H)-one (132 mg, 0.430 mmol) and tert -butyl azepan-3-ylcarbamate (111 mg, 0.516 mmol) were mixed with Example 134. By reacting in the same manner, 55.8 mg of a labeled compound was obtained as an ivory solid.
- Example 144 N-(1-(3-cyclohexyl-4-oxo-3,4-dihydrophthalazine-1-yl) azepan-3-yl) ethanesulfonamide
- Example 143 The compound of Example 143 (30 mg, 0.080 mmol) was reacted in the same manner as in Step 3 of Example 128 to obtain 18 mg of the title compound as a white solid.
- Example 146 The compound of Example 146 (30 mg, 0.083 mmol) was reacted in the same manner as in Step 3 of Example 128 to obtain 6 mg of the title compound as a pale yellow compound.
- Example 148 4-(3-aminoazepan-1-yl)-2-(4-fluorophenyl)phthalazine-1(2H)-one hydrochloride
- Step 1 2-(4-fluorophenyl)-1-oxo-1,2-dihydropyrido[3,4-d]pyridazin-4-yl trifluoromethanesulfonate (64 mg, 0.164 mmol ), (3-aminophenyl) boronic acid (24.77 mg, 0.181 mmol), lithium chloride (20.91 mg, 0.493 mmol), Pd(PPh 3 ) 4 (19 mg, 0.016 mmol) and 2M Na 2 CO 3 aqueous solution (247 ⁇ L, 0.493 mmol) was diluted in 1.6 mL of toluene and stirred at 100-110 °C for 3 hours.
- reaction solution was cooled to room temperature, diluted with EA, and washed with purified water.
- the organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, separated by column chromatography, and 35 mg of 4-(3-aminophenyl)-2-(4-fluorophenyl)pyrido[3,4] as a pale yellow solid. -d]pyridazin-1(2H)-one was obtained.
- Step 2 The compound obtained in Step 1 (35 mg, 0.105 mmol) was reacted in the same manner as in Step 3 of Example 128 to obtain 16 mg of the title compound as a pale yellow solid.
- Example 150 N-(3-(3-(4-fluorophenyl)-8-methyl-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)ethanesulfonamide
- Step 1 A white solid by reacting 4-methylisobenzofuran-1,3-dione (500 mg, 3.08 mmol) and (3-aminophenyl) boronic acid (602 mg, 3.7 mmol) in a similar manner to Preparation Example 4 281 mg of 3-(4-fluorophenyl)-8-methyl-4-oxo-3,4-dihydrophthalazin-1-yl trifluoromethanesulfonate were obtained.
- Step 2 The compound obtained in Step 1 (76 mg, 0.189 mmol) was reacted in the same manner as in Example 149 to obtain 29 mg of the title compound as a white solid.
- Example 151 N-(3-(4-oxo-3-(tetrahydro-2H-pyran-4-yl)-3,4-dihydrophthalazin-1-yl)phenyl)ethanesulfonamide
- Example 152 2-(3-(3-(4-fluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-2-methylpropionic acid
- Step 1 Compound I-2 (110 mg, 0.345 mmol) and methyl 2-methyl-2-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2- I) phenyl) propionate (115 mg, 0.0.379 mmol) was reacted in the same manner as in Step 1 of Example 1 to obtain 82 mg of methyl 2-(3-(3-(4-fluorophenyl) as a white solid) )-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)-2-methylpropionate was obtained.
- Step 2 The compound obtained from Step 1 (82 mg, 0.197 mmol) and 2M NaOH aqueous solution (148 ⁇ L, 0.295 mmol) were diluted in MeOH and THF, followed by stirring at 40° C. for 2 hours. After the reaction solution was concentrated, purified water was added, and the pH was adjusted to 6-7 with 1N HCl, followed by extraction with DCM. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and crystallized with diethyl ether to obtain 50 mg of the title compound as a white solid.
- Example 152 The compound of Example 152 (44 mg, 0.109 mmol), methylamine HCl (8.86 mg, 0.131 mmol) and DIPEA (57.3 ⁇ L, 0.328 mmol) were diluted in DMF (0.4 mL), cooled at 0 to 5 °C, and then PyBOP ( 85 mg, 0.164 mmol) was added, the temperature was gradually raised to room temperature, and the mixture was stirred for 18 hours.
- the reaction solution was diluted with EA, washed with purified water, and the organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 22 mg of the title compound as a white solid.
- Example 154 2-cyclohexyl-4-(3-(methyl Sulfonyl )Phenyl)phthalazine-1(2H)-one
- Step 1 4-bromo-2-cyclohexylphthalazine-1 (2H)-one (250 mg, 0.814 mmol) and tert-butyl (S)-azepan-3-ylcarbamate (209 mg, 0.977 mmol) in the same manner as in Step 1 of Example 134 to react white solid 108 mg of tert -butyl (S)-(1-(3-cyclohexyl-4-oxo-3,4-dihydrophthalazine-) 1-yl)azepan-3-yl)carbamate was obtained.
- Step 2 After 60% NaH washed with THF was diluted in THF (221 ⁇ L) and cooled to 0° C., the compound obtained from Step 1 (30 mg, 0.066 mmol) was added and stirred at the same temperature for 12 minutes. Thereafter, iodomethane (37.6 mg, 0.265 mmol) was added at 0° C., and the temperature was gradually raised to room temperature, followed by stirring for 4 hours. The reaction solution was diluted with EA and washed with purified water.
- Step 3 The compound obtained from Step 2 (22 mg, 0.047 mmol) was reacted in the same manner as in Step 2 of Example 7 to obtain 11.6 mg of the title compound as a white solid.
- Step 1 After diluting compound I-9 (22 mg, 0.054 mmol) and tert -butyl (S) -azepan -3-ylcarbamate (29 mg, 0.135 mmol) in DMSO, at 90° C. for 1 hour Stirred. The reaction solution was cooled to room temperature, diluted with EA, and washed with purified water. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, separated by column chromatography, and 14 mg tert -butyl (S)-(1-(3-(2,4-difluorophenyl)-4) as a white solid. -Oxo-3,4-dihydrophthalazin-1-yl)azepan-3-yl)carbamate was obtained.
- Step 2 The compound obtained from Step 1 (14 mg, 0.030 mmol) was reacted in the same manner as in Step 2 of Example 134 to obtain 2.2 mg of the title compound as a light brown solid.
- Step 1 Compound I-2 (250 mg, 0.783 mmol) and (3-aminophenyl) boronic acid (118 mg, 0.862 mmol) were reacted in the same manner as in Step 1 of Example 1 to obtain 80 mg of 4 as an ocher solid. -(3-Aminophenyl)-2-(4-fluorophenyl)phthalazine-1(2H)-one was obtained.
- Step 2 The compound obtained from Step 1 (30 mg, 0.091 mmol) and ethylene carbonate (39.9 mg, 0.453 mmol) were diluted in DBU (13.65 ⁇ L, 0.091 mmol) and stirred at 100° C. for 3 hours. After cooling the reaction solution to room temperature, it was diluted with DCM and washed with purified water. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 20.7 mg of the title compound as a pale yellow solid.
- DBU 13.65 ⁇ L, 0.091 mmol
- Example 160 The compound of Example 160 (14 mg, 0.036 mmol) and ammonium chloride (2.88 mg, 0.054 mmol) were reacted in the same manner as in Example 153 to obtain 8.6 mg of the title compound as a white solid.
- Example 160 The compound of Example 160 (14 mg, 0.036 mmol) and methylamine hydrochloride (3.63 mg, 0.054 mmol) were reacted in the same manner as in Example 153 to obtain 9.2 mg of the title compound as a white solid.
- Example 166 2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-2-methylpropionic acid
- Example 167 4-(3-aminoazepan-1-yl)-2-(2,4-difluorophenyl)phthalazine-1(2H)-one hydrochloride
- Example 168 The compound of Example 168 (50 mg, 0.125 mmol), NaN 3 (10.53 mg, 0.162 mmol) and ammonium chloride (9.99 mg, 0.187 mmol) were diluted in DMF and stirred at 100° C. for 16 hours. The reaction solution was cooled to room temperature, diluted with EA, and washed with purified water. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 3.1 mg of the title compound as a pale yellow solid.
- Example 170 (E)-2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-N' -Hydroxy-2-methylpropaneimideamide
- Example 168 The compound of Example 168 (100 mg, 0.249 mmol), NaHCO 3 (41.9 mg, 0.498 mmol) and hydroxylamine hydrochloride (24.23 mg, 0.349 mmol) were diluted in EtOH and stirred at 80° C. for 27 hours.
- the reaction solution was cooled to room temperature, diluted with EA, and washed with purified water.
- the organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 11.4 mg of the title compound as a white solid.
- Example 170 The compound of Example 170 (40 mg, 0.092 mmol), p-TsOH (5.25 mg, 0.028 mmol) and ZnCl 2 (3.76 mmol, 0.028 mmol) were diluted in CAN and stirred at 82° C. for 17 hours.
- the reaction solution was cooled to room temperature, diluted with EA, and washed with purified water and saturated NaHCO 3 aqueous solution.
- the organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 12.5 mg of the title compound as a white solid.
- Example 176 2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4,-dihydrophthalazine-1-yl)phenyl)-N-isopropyl- 2-methylpropanamide
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and propan-2-amine hydrochloride (17.05 mg, 0,178 mmol) were reacted in the same manner as in Example 153 to obtain 16.4 mg of the title compound as a pale yellow solid.
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and pyrrolidine (12.69 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 30.7 mg of the title compound as a white solid.
- Example 178 N-cyclopropyl-2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)-2 -Methylpropanamide
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and cyclopropanamine (10.19 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 7.8 mg of the title compound as a pale yellow solid.
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and morpholine (15.54 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 10.1 mg of the title compound as a white solid.
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and cyclohexanamine (17.69 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 34.7 mg of the title compound as a white solid.
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and aniline (16.61 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 10.3 mg of the title compound as a white solid.
- Example 182 2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4,-dihydrophthalazin-1-yl)phenyl)-2-methyl-N -(1-methyl-1H-pyraol-4-yl)propanamide
- Example 166 The compound of Example 166 (50 mg, 0.119 mmol) and 1-methyl-1H-pyraol-4-amine (17.33 mg, 0.178 mmol) were reacted in the same manner as in Example 153 to obtain 22.8 mg of the title as a pale orange solid. The compound was obtained.
- Example 184 4-(1,4-diazepan-1-yl)-2-(2,4-difluorophenyl)phthalazine-1(2H)-one hydrochloride
- Step 1 The compound of Example 166 (100 mg, 0.238 mmol) and 2-((tert-butyldimethylsilyl)oxy)ethan-1-amine (62.6 mg, 0.357 mmol) were reacted in the same manner as in Example 153. 50 mg of N-(2-((tert-butyldimethylsilyl)oxy)ethyl)-2-(3-(3-(2,4-difluorophthal)-4-oxo-3,4-dihyde Loftalazin-1-yl)phenyl)-2-methylpropanamide was obtained.
- Step 2 After dissolving the compound (50 mg, 0.087 mmol) obtained from step 1 in THF (433 ⁇ L), 1 M TBAF in THF (104 ⁇ L, 0.104 mmol) was added dropwise at -5 °C, followed by stirring for 40 minutes. I did. Water (10 mL) was added to the reaction solution, diluted with EA, and washed with purified water. The organic layer was dehydrated with Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 17 mg of the title compound as a white solid.
- Example 188 2-(3-(3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazine-1-yl)phenyl)-2-methylpropanamide
- Example 166 The compound of Example 166 (33 mg, 0.078 mmol) and ammonium chloride (6.3 mg, 0,178 mmol) were reacted in the same manner as in Example 153 to obtain 10.7 mg of the title compound as a white solid.
- Step 1 After dissolving the compound of Example 165 (50 mg, 0.123 mmol) in DMF, calcium carbonate (51.0 mg, 0.369 mmol) and iodomethane (17.44 mmol, 0.123 mmol) were added, followed by stirring at 50 °C for 18 hours. I did.
- reaction product was diluted with EA and washed with purified water, and the separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, separated by column chromatography, and 20 mg of tert-butyl (R)-(1- (3-(2,4-difluorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)azepan-3-yl)(methyl)carbamate was obtained.
- Step 2 After dissolving the compound (20 mg, 0.052 mmol) obtained from step 1 in DCM, 4 M HCl in dioxane (65.0 ⁇ L, 0.260 mmol) was slowly added dropwise at 0° C. and stirred for 1 hour. The reaction solution was concentrated under reduced pressure to obtain 7.8 mg of the title compound as a pale yellow solid.
- Step 1 After dissolving azepanone (200 mg, 1.767 mmol) in methanol, sodium hydrogen carbonate (66.9 mg, 1.767 mmol) was slowly added at 0 °C, followed by stirring at room temperature for 3 hours. The reaction product was concentrated under reduced pressure, water was added, the pH was adjusted to 8 to 9 with 1N HCl, diluted with EA, and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 98 mg of azepanol as a pale yellow oil.
- Step 2 The compound obtained from Step 1 (25 mg, 0.217 mmol) and 3-(4-chlorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl trifluoromethanesulfonate ( 76.5 mg, 0.181 mmol) and DIPEA (63.2 ⁇ L, 0.362 mmol) were reacted in the same manner as in Example 165 to obtain 3 mg of the title compound as a white solid.
- Step 1 After dissolving the compound of Example 165 (50 mg, 0.123 mmol) in DMF (2-bromoethoxy) (tert-butyl) dimethylsilian (32.3 mg, 0.135 mmol) and cesium carbonate (80 mg, 0.246) mmol) was added, followed by stirring at 50° C. for 16 hours.
- reaction product was diluted with EA and washed with purified water, and the separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, separated by column chromatography, and used as a pale yellow oil of 26 mg (R)-4-(3-( (2-((tert-butyldimethylsilyl)oxy)ethyl)amino)azepan-1-yl)phthalazine-1(2H)-one was obtained.
- Step 2 After dissolving the compound (44.4 mg, 0.084 mmol) obtained from step 1 in DCM, 4 M HCl in dioxane (840 ⁇ L, 3.36 mmol) was slowly added dropwise at 0 °C, followed by stirring at room temperature for 1 hour and a half. After adding water to the reaction product, the pH was adjusted to 9 using a saturated solution of NaHCO 3 , and the reaction target was extracted with EA and washed with purified water. The organic layer was dehydrated with anhydrous Na 2 SO 4 and concentrated under reduced pressure to obtain 22.8 mg of (R)-2-(2,4-difluorophenyl)-4-(3-((2-hydroxyethyl) as a pale yellow oil. Amino)azepan-1-yl)phthalazine-1(2H)-one was obtained.
- Step 3 The compound obtained from Step 2 (22.8 mg, 0.055 mmol) was reacted in the same manner as in Step 2 of Example 189 to obtain 10.8 mg of the title compound as a white solid.
- Example 165 The compound of Example 165 (50 mg, 0.123 mmol) and acetyl chloride were reacted in the same manner as in Example 187 to obtain 12 mg of the title compound as a white solid.
- Example 190 The compound of Example 190 (38.5 mg, 0.104 mmol) was dissolved in DCM, and then Dess-Martin periodinane (44 mg, 0.104 mmol) was added at 0 °C, followed by stirring at room temperature for 23 hours.
- the reaction product was diluted with DCM and washed with purified water, and the separated organic layer was dehydrated with anhydrous Na 2 SO 4 , concentrated under reduced pressure, and separated by column chromatography to obtain 5.7 mg of the title compound as a white solid.
- Example 195 1-(3-(3-(4-chlorophenyl)-4-oxo-3,4-dihydrophthalazin-1-yl)phenyl)cyclopropane-1-carboxylic acid
- Example 194 The compound of Example 194 (50 mg, 0.119 mmol) was reacted in the same manner as in Example 163 to obtain 37.2 mg of the title compound as a white solid.
- Example 195 The compound of Example 195 (11 mg, 0.026 mmol) was reacted in the same manner as in Example 163 to obtain 6.7 mg of the title compound as a white solid.
- Example 200 4-(3-(2-aminopropan-2-yl)phenyl)-2-(2,4-difluorophenyl) phthalazine-1(2H)-one hydrochloride
- Step 1 Compound I-9 (19.7 mg, 0.048 mmol) and 2-(3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl) Carbamate (21 mg, 0.058 mmol) was reacted in the same manner as in Example 152, and 14.5 mg of tert-butyl (2-(3-(4,4,5,5-tetramethyl-1,3, 2-dioxaborolan-2-yl)phenyl)propan-2-yl)carbamate was obtained.
- Step 2 The compound obtained from Step 1 (21 mg, 0.058 mmol) was reacted in the same manner as in Step 2 of Example 157 to obtain 8.3 mg of the title compound as a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
실시예 | 화합물 명칭 | Sirt6 활성 (%활성, 10μM) | |
1 | N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 170 | |
2 | 4-(3-아미노페닐)-2-(4-(트리플루오로메틸)페틸)프탈라진-1(2H)-온 | 88 | |
3 | N-(3-(4-옥소-3-(4-(트리플루오로메틸)페닐)-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 104 | |
4 | 4-(3-(에틸아미노)페닐)-2-(4-(트리플루오로메틸) 페닐)프탈라진-1(2H)-온 | 102 | |
5 | N-메틸-N-(3-(4-옥소-3-(4-(트리플루오로메틸)페닐)- 3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 105 | |
6 | N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드 | 102 | |
7 | N-메틸-N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드 | 173 | |
8 | N-(4-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 100 | |
9 | N-(3-(3-페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-디메틸설파모일아미드 | 154 | |
10 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드 | 198 | |
11 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 162 | |
12 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-디메틸설파모일아미드 | 189 | |
13 | (Z)-N-메틸-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 181 | |
14 | (Z)-N-이소프로필-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 121 | |
15 | (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 231 | |
16 | (Z)-N-에틸-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 221 | |
17 | (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 207 | |
18 | N-(2-클로로-5-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)-N-(메틸설포닐)메탄설폰아미드 | 114 | |
19 | N-(3-(3-(페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-6-클로로페닐)-디메틸설파모일아미드 | 120 | |
20 | 메틸 (N-(3-(3-(4-플루오로페닐)-4-옥소-3,4- 디하이드로프탈라진-1-일)페닐)설파모일)카바메이트 | 211 | |
21 | (Z)-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 167 | |
22 | (Z)-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 201 | |
23 | (Z)-N-터트-부틸-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 192 | |
24 | 4-(3-아미노페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 | 147 | |
25 | N-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 147 | |
26 | 메틸 (N-(3-(3-(2,4-디플루오로페닐)-4-옥소- 3,4-디하이드로프탈라진-1-일)페닐)설파모일)카바메이트 | 180 | |
27 | (Z)-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 148 | |
28 | (Z)-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 154 | |
29 | (Z)-N-터트-부틸-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 162 | |
30 | N-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 117 | |
31 | (Z)-1-(3-(3-(3,5-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 171 | |
32 | (Z)-N-이소프로필-1-(3-(3-(4-메톡시페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 124 | |
33 | (Z)-1-(3-(3-(3-클로로-4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 183 | |
34 | (Z)-N-터트-부틸-1-(3-(3-(3-클로로-4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 176 | |
35 | (Z)-N-벤질l-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 113 | |
36 | (E)-1-(4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 142 | |
37 | (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 126 | |
38 | (E)-1-(3-플루오로-4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 143 | |
39 | (E)-1-(3-플루오로-4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 106 | |
40 | (Z)-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 160 | |
41 | (Z)-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 129 | |
42 | (Z)-N-터트-부틸-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 161 | |
43 | (Z)-N-터트-부틸-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 205 | |
44 | (Z)-N-벤질-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 142 | |
45 | (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)-N-메틸메탄이민 옥시드 | 195 | |
46 | (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)-N-이소프로필메탄이민 옥시드 | 154 | |
47 | (Z)-N-터트-부틸-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)메탄이민 옥시드 | 132 | |
48 | (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)퓨란-2-일)-N-이소프로필메탄이민 옥시드 | 107 | |
49 | (Z)-N-터트-부틸-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-2-메톡시페닐)메탄이민 옥시드 | 107 | |
50 | (Z)-N-벤질-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-2-메톡시페닐)메탄이민 옥시드 | 105 | |
51 | (Z)-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 139 | |
52 | (Z)-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 172 | |
53 | (Z)-N-터트-부틸-1-(2-플루오로-5-(3-(4-플루오로 페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 172 | |
54 | (Z)-N-벤질-1-(2-플루오로-5-(3-(4-플루오로페닐)- 4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 161 | |
55 | (Z)-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소- 3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 151 | |
56 | (Z)-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소- 3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 115 | |
57 | (Z)-N-터트-부틸-1-(4-플루오로-3-(3-(4-플루오로 페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 149 | |
58 | (Z)-N-벤질-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 131 | |
59 | 4-(4-클로로-3-니트로페닐)-2-(4-플루오로페닐)프탈라진-1(2H)-온 | 109 | |
60 | 4-(3-아미노페닐)-2-(4-플루오로페닐)프탈라진- 1(2H)-온 | 176 | |
61 | N-(3-(3-벤질-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 104 | |
62 | N-(3-(4-옥소-3-페네틸-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 111 | |
63 | N-(3-(3-(4-플루오로벤질)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 103 | |
64 | N-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 106 | |
65 | N-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸에탄설폰아미드 | 96 | |
66 | 메틸 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로 프탈라진-1-일)벤조에이트 | 103 | |
67 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)프로판-2-설폰아미드 | 166 | |
68 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)프로판-1-설폰아미드 | 160 | |
69 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄설폰아미드 | 209 | |
70 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸에탄설폰아미드 | 135 | |
71 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판설폰아미드 | 150 | |
72 | N-(3-(3-(4-플로오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸프로판-1-설폰아미드 | 115 | |
73 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸프로판-2-설폰아미드 | 124 | |
74 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸시클로프로판설폰아미드 | 128 | |
75 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸-디메틸설파모일아미드 | 139 | |
76 | 메틸 (N-(3-(3-(4-플루오로페닐)-4-옥소-3,4- 디하이드로프탈라진-1-일)페닐)-N-메틸설파모일)(메틸)카바메이트 | 125 | |
77 | 1,1,1-트리플루오로-N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드 | 194 | |
78 | 1,1,1-트리플루오로-N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄설폰아미드 | 122 | |
79 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-((테트라하이드로-2H-피란-2-일)옥시)벤즈아미드 | 167 | |
80 | N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸-메틸설파모일아미드 | 216 | |
81 | 4-(3-(1H-테트라졸-5-일)페닐)-2-(4-플루오로페닐)프탈라진-1(2H)-온 | 115 | |
82 | N-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘-3-일)에탄설폰아미드 | 111 | |
83 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-히드록시벤즈아미드 | 162 | |
84 | (Z)-1-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 123 | |
85 | (Z)-1-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 118 | |
86 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 196 | |
87 | N-에틸-3-(3-(4-플로오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드 | 226 | |
88 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메일벤젠설폰아미드 | 180 | |
89 | 2-(2,4-디플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온 | 339 | |
90 | 2-(2,4-디플루오로페닐)-4-(3-(에틸설폰닐)페닐)프탈라진-1(2H)-온 | 283 | |
91 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 272 | |
92 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드 | 208 | |
93 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드 | 227 | |
94 | (Z)-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 272 | |
95 | (Z)-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 133 | |
96 | (Z)-N-터트-부틸-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 176 | |
97 | 2-(2-플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온 | 286 | |
98 | 4-(3-(에틸설포닐)페닐)-2-(2-플루오로페닐)프탈라진-1(2H)-온 | 264 | |
99 | 3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 259 | |
100 | N-에틸-3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드 | 196 | |
101 | 3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드 | 153 | |
102 | (Z)-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드 | 206 | |
103 | (Z)-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드 | 324 | |
104 | (Z)-N-터트-부틸-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드 | 284 | |
105 | 2-(2,6-디플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온 | 226 | |
106 | 2-(2,6-디플루오로페닐)-4-(3-(에틸설포닐)페닐)프탈라진-1(2H)-온 | 141 | |
107 | 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 233 | |
108 | 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드 | 209 | |
109 | 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드 | 188 | |
110 | 6-플루오로-4-(3-(메틸설포닐)페닐)-2-페닐프탈라진-1(2H)-온 | 129 | |
111 | 3-(7-플루오로-4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 126 | |
112 | 7-플루오로-4-(3-(메틸설포닐)페닐)-2-페닐프탈라진-1(2H)-온 | 103 | |
113 | 3-(6-플루오로-4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 116 | |
114 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드 | 226 | |
115 | 2-(2,4-디플루오로페닐)-4-(피리딘-3-일)프탈라진-1(2H)-온 | 405 | |
116 | 2-(2,6-디플루오로페닐)-4-(피리딘-3-일)프탈라진-1(2H)-온 | 227 | |
117 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드 | 318 | |
118 | 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드 | 231 | |
119 | 2-(2,4-디플루오로페닐)-6-플루오로-4-(3-(메틸 설포닐)페닐)프탈라진-1(2H)-온 | 166 | |
120 | 2-(2,4-디플루오로페닐)-7-플루오로-4-(3-(메틸 설포닐)페닐)프탈라진-1(2H)-온 | 178 | |
121 | 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 157 | |
122 | 3-(3-(2,4-디플루오로페닐)-6-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드 | 177 | |
123 | 2-(2,4-디플루오로페닐)-4-(3-(에틸설포닐)페닐)-6-플루오로프탈라진-1(2H)-온 | 253 | |
124 | 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드 | 146 | |
125 | 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드 | 172 | |
126 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드 | 185 | |
127 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-(2-히드록시에틸)벤젠설폰아미드 | 321 | |
128 | N-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 177.53 | |
129 | N-(3-(3-(1-메틸피페리딘-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 104.16 | |
130 | 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤조니트릴 | 120.16 | |
131 | (E)-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N'-히드록시벤즈이미드아미드 | 102.08 | |
132 | N-(3-(3-이소프로필-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 107.58 | |
133 | N-(3-(3-(1-메틸-1H-피라졸-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탈설폰아미드 | 118.8 | |
134 | 4-(3-아미노피페리딘-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 167.53 | |
135 | N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드 | 174.93 | |
136 | N-(3-(3-(옥세탄-3-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 101.27 | |
137 | N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피롤리딘-3-일)에탄설폰아미드 | 112.58 | |
138 | (S)-N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드 | 175.98 | |
139 | (R)-N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드 | 130.07 | |
140 | N-(3-(3-(4,4-디플루오로시클로헥실)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 134.41 | |
141 | N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드 | 212.55 | |
142 | 3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드 | 162.3 | |
143 | 4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진- 1(2H)-온·하이드로클로라이드 | 238.3 | |
144 | N-(1-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드 | 164.1 | |
145 | N-(3-(3-(4-메틸시클로헥실)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 136.6 | |
146 | (S)-4-(3-아미노피페리딘-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드 | 135.2 | |
147 | (S)-N-(1-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드 | 127.7 | |
148 | 4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 184.3 | |
149 | N-(3-(2-(4-플루오로페닐)-1-옥소-1,2-디하이드로피리도[3,4-d]피리딘-4-일)페닐)에탄설폰아미드 | 114.9 | |
150 | N-(3-(3-(4-플루오로페닐)-8-메틸-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 104.7 | |
151 | N-(3-(4-옥소-3-(테트라하이드로-2H-피란-4-일)-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드 | 145.64 | |
152 | 2-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 195.5 | |
153 | 2-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N,2-디메틸프로판아미드 | 280.4 | |
154 | 2-시클로헥실-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온 | 263.7 | |
155 | (S)-4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드 | 230.9 | |
156 | (S)-2-시클로헥실-4-(3-(메틸아미노)아제판-1-일)프탈라진-1(2H)-온·하이드로클로라이드 | 223.9 | |
157 | (S)-4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 244.1 | |
158 | (S)-4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 164.7 | |
159 | (R)-4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드 | 398.8 | |
160 | 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 289.8 | |
161 | 3-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)옥사졸리딘-2-온 | 177 | |
162 | (R)-4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 205.5 | |
163 | 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드 | 277 | |
164 | 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N,2-디메틸프로판아미드 | 285.5 | |
165 | (R)-4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 277.1 | |
166 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 239.2 | |
167 | 4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 249.4 | |
168 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판니트릴 | 155.7 | |
169 | 4-(3-(2-(1H-테트라졸-5-일)프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 | 211.3 | |
170 | (E)-2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N'-히드록시-2-메틸프로판이미드아미드 | 262.7 | |
171 | 2-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 134.7 | |
172 | 4-(3-아미노아제판-1-일)-2-시클로부틸프탈라진- 1(2H)-온·하이드로클로라이드 | 99.5 | |
173 | 4-(3-아미노아제판-1-일)-2-시클로펜틸프탈라진- 1(2H)-온·하이드로클로라이드 | 112.2 | |
174 | 2-(2,4-디플루오로페닐)-4-(3-(2-(5-메틸-1,2,4-옥사디아졸-3-일)프로판-2-일)페닐)프탈라진-1(2H)-온 | 114.2 | |
175 | (R)-4-(3-아미노아제판-1-일)-2-(2-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드 | 155.3 | |
176 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)페닐)-N-이소프로필-2-메틸프로판아미드 | 244.30 | |
177 | 2-(2,4-디플루오로페닐)-4-(3-(2-메틸-1-옥소-1-(피롤리딘-1-일)프로판-2-일)페닐)프탈라진-1(2)-온 | 241.6 | |
178 | N-사이클로프로필-2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드 | 331.00 | |
179 | 2-(2,4,-디플루오로페닐)-4-(3-(2-메틸-1-몰폴리노-1-옥소프로판-2-일)페닐)프탈라진-1(2H)-온 | 221.60 | |
180 | N-시클로헥실-2-(3-(3-(2,4-디플루오페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드 | 133.30 | |
181 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸-N-페닐프로판아미드 | 122.10 | |
182 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)페닐)-2-메틸-N-(1-메틸-1H-피라졸-4-일)프로판아미드 | 219.60 | |
183 | 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복실산 | 194.70 | |
184 | 4-(1,4-디아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드 | 176.80 | |
185 | (R)-4-(3-아미노아제판-1-일)-2-(4-클로로페닐)프탈라진-1(2H)-온 하이드로클로라이드 | 273.80 | |
186 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-(2-히드록시에틸)-2-메틸프로판아미드 | 305.80 | |
187 | (R)-N-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드 | 303.80 | |
188 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드 | 358.40 | |
189 | (R)-2-(2,4-디플루오루페닐)-4-(3-(메틸아미노)아제판-1-일)프탈라진-1(2H)-온 하이드로클로라이드 | 273.70 | |
190 | 2-(2,4-디플루오로페닐)-4-(3-히드록시아제판-1-일)프탈라진-1(2H)-온 | 332.60 | |
191 | (R)-2-(2,4-디플루오로페닐)-4-(3-((2-히드록시에틸)아미노)아제판-1-일)프탈라진-1(2H)-온 하이드로클로라이드 | 312.70 | |
192 | (R)-N-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)아세트아미드 | 286.60 | |
193 | 2-(2,4-디플루오로페닐)-4-(3-옥소아제판-1-일)프탈라진-1(2H)-온 | 206.10 | |
194 | 2-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 350.20 | |
195 | 1-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복실산 | 287.30 | |
196 | 2-(4-클로로페닐)-4-(3-히드록시아제판-1-일)프탈라진-1(2H)-온 | 135.10 | |
197 | 2-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드 | 153.60 | |
198 | 1-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복시아미드 | 225.40 | |
199 | 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)아세트산 | 149.41 | |
200 | 4-(3-(2-아미노프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드 | 255.33 | |
201 | 2-(3-(3-(4-클로로-2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 204.58 | |
202 | (R)-4-(3-아미노아제판-1-일)-2-(4-클로로-2-플루오로페닐)프탈라진-1-(2H)-온 하이드로클로라이드 | 261.73 | |
203 | 1-(3-(4-클로로-2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-카보니트릴 | 109.84 | |
204 | 4-(3-(1-아미노-2-메틸프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드 | 161.50 | |
205 | 2-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산 | 105.70 | |
206 | 2-(3-(3-(4-시클로프로필페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산 | 182.70 | |
207 | 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로부탄-1-카복실산 | 309.90 | |
208 | 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로펜탄-1-카복실산 | 117.30 | |
209 | 2-(1-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산 | 169.10 | |
210-1 | 2-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산 | 199.00 | |
210-2 | 2-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산 | 100.50 | |
211 | 메틸 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4- 디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실레이트 | 170.00 | |
212 | 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실산 | 170.10 | |
213-1 | 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실산 | 168.10 | |
213-2 | 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실산 | 102.60 | |
214 | 2-(2,4-디플루오로페닐)-4-(3-(피롤리딘-1-일설포닐)페닐)프탈라진-1(2H)-온 | 233.90 | |
215 | 2-(2,4-디플루오로페닐)-4-(1,2,3,6-테트라하이드로피리딘-4-일)프탈라진-1(2H)-온 하이드로클로라이드 | 226.60 | |
216 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸-N-메틸벤젠설폰아미드 | 184.80 | |
217 | 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디에틸벤젠설폰아미드 | 185.10 | |
218 | 2-(2,4-디플루오로페닐)-4-(1-(에틸설포닐)-1,2,3,6-테트라하이드로피리딘-4-일)프탈라진-1(2H)-온 | 176.50 | |
219 | 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디히들프탈라진-1-일)피페라진-2-일)-2-메틸프로피온산 | 114.60 | |
220 | 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-1-메틸피페라진-2-일)-2-메틸프로피온산 | 125.80 | |
221 | 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)몰포린-2-일)-2-메틸프로피온산 | 125.50 |
Claims (15)
- 하기 화학식 1로 표시되는 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염:화학식 1식 중에서,X는 CH 또는 N이고,R 1은 H, C 1-6 알킬, 또는 플루오로, 클로로 및 브로모로 구성된 군에서 선택되는 할로이고,R 2는 C 1-6 알킬, 아릴 치환 C 1-6 알킬, 아릴, 헤테로아릴, C 3-7 시클로알킬 및 헤테로사이클릴로 구성된 군에서 선택되고,R 3은 아릴, 헤테로아릴 및 헤테로사이클릴로 구성된 군에서 선택되며,상기 아릴, 헤테로아릴, 시클로알킬 및 헤테로사이클릴은 각각 1 내지 3개의 치환기로 치환될 수 있고, 이들이 치환되는 경우 그 치환기는 각각 독립적으로 플루오로, 클로로 및 브로모로 구성된 군에서 선택되는 할로, 니트로, 시아노, 히드록시, 옥소, 비치환 또는 1 내지 3개의 할로겐 원자로 치환된 C 1-6 알킬, C 1-6 알킬옥시, 아릴, 헤테로아릴, -NR 4R 5, -CH=N +(O -)R 6, -C(O)R 7, -SO 2R 8, -C(=NOH)NR 9R 10 및 -CR 9R 10R 11로 구성된 군에서 선택되며,R 4 및 R 5는 각각 독립적으로 H, C 1-6 알킬, 1 내지 3개의 할로겐 원자 또는 히드록시로 치환된 C 1-6 알킬, -SO 2R 12 또는 -C(O)R 15이고,R 6은 C 1-6 알킬 또는 아릴 치환 C 1-6 알킬이고,R 7은 C 1-6 알킬옥시 또는 -NR 16R 17이고,R 8은 C 1-6 알킬 또는 -NR 18R 19이고,R 9 및 R 10은 각각 독립적으로 H 또는 C 1-6 알킬이거나, 또는 R 9과 R 10은 서로 결합하여 이들이 결합된 탄소 원자와 함께 시클로알킬을 형성하고,R 11은 시아노, 아미노, 비치환 또는 아미노 치환 C 1-6 알킬, 비치환 또는 C 1-6 알킬 치환 헤테로아릴, 헤테로사이클릴, -CO 2R 20 또는 -C(O)NR 20R 21이고,R 12는 C 1-6 알킬, 1 내지 3개의 할로겐 원자로 치환된 C 1-6 알킬, C 3-6 시클로알킬 또는 -NR 13R 14이고,R 13 및 R 14는 각각 독립적으로 H, C 1-6 알킬 또는 -CO 2R 15이고,R 15는 -C 1-6 알킬이고,R 16 및 R 17은 각각 독립적으로 H, 헤테로사이클릴옥시 또는 히드록시이고,R 18 및 R 19는 각각 독립적으로 H, 비치환 또는 히드록시 치환 C 1-6 알킬이거나, 또는 R 18과 R 19는 서로 결합하여 이들이 결합된 N 원자와 함께 헤테로사이클릴이 되고,R 20은 H 또는 C 1-6 알킬이고, R 21은 H, 비치환 또는 히드록시 치환 C 1-6 알킬, 시클로알킬, 아릴, 또는 비치환 또는 C 1-6 알킬 치환 헤테로아릴이거나, 또는 R 20과 R 21은 서로 결합하여 이들이 결합된 N 원자와 함께 헤테로사이클릴을 형성하고,상기 아릴은 C 6-10 방향족 고리기이고,상기 시클로알킬은 C 3-7 지방족 고리기이고,상기 헤테로아릴은 고리 내에 N, O 및 S 중에서 선택되는 1 내지 4개의 헤테로 원자를 포함하는 5원 또는 6원 헤테로 방향족 고리기이고,상기 헤테로사이클릴은 고리 내에 N 및 O 중에서 선택되는 1 내지 2개의 헤테로 원자를 포함하는 4 내지 7원 헤테로 고리기이다.
- 제1항에 있어서,R 2가 C 1-6 알킬; C 6-10 아릴로 치환된 C 1-6 알킬; 비치환 C 6-10 아릴; C 1-6 알킬, 플루오로 치환 C 1-6 알킬, C 1-6 알킬옥시, 플루오로, 클로로 및 브로모로 구성된 군에서 선택되는 1 내지 2개의 치환기로 치환된 C 6-10 아릴; 비치환 C 3-7 시클로알킬; 플루오로, 클로로, 브로모 및 C 1-6 알킬로 구성된 군에서 선택되는 1 내지 2개의 치환기로 치환된 C 3-7 시클로알킬; 비치환 헤테로아릴; 또는 C 1-6 알킬로 치환된 헤테로아릴인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 있어서,R 3은 플루오로, 클로로 및 브로모로 구성된 군에서 선택되는 할로, 니트로, 시아노, 비치환 또는 1 내지 3개의 할로겐 원자로 치환된 C 1-6 알킬, C 1-6 알킬옥시, 아릴 및 헤테로아릴로 구성된 군에서 선택되는 기로 치환된 아릴인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -NR 4R 5로 더 치환된 아릴이고,R 4는 H, C 1-6 알킬 또는 C 1-6 알킬설포닐이고,R 5는 H, 비치환 또는 히드록시 치환 C 1-6 알킬, -C(O)R 15 또는 -SO 2R 12이고,R 12는 C 1-6 알킬, 플루오로 치환 C 1-6 알킬, C 3-6 시클로알킬 또는 -NR 13R 14이고,R 13 및 R 14는 각각 독립적으로 H, C 1-6 알킬 또는 -CO 2R 15이고,R 15는 -C 1-6 알킬인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -CH=N +(O -)R 6으로 더 치환된 아릴이고, R 6은 C 1-6 알킬 또는 아릴 치환 C 1-6 알킬인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -C(O)R 7로 더 치환된 아릴이고, R 7은 -NR 16R 17이고, R 16은 H이고, R 17은 H, 헤테로사이클릴옥시 또는 히드록시인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -SO 2R 8로 더 치환된 아릴이고, R 8은 -NR 18R 19이고, R 18은 H 또는 C 1-6 알킬이고, R 19는 H, C 1-6 알킬 또는 히드록시 치환 C 1-6 알킬이거나, 또는 R 18과 R 19는 서로 결합하여 이들이 결합된 N 원자와 함께 헤테로사이클릴을 형성하는 것인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -C(=NOH)NR 9R 10로 더 치환된 아릴이고, R 9 및 R 10은 각각 H인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제3항에 있어서,R 3은 치환기 -CR 9R 10R 11로 더 치환된 아릴이고, R 9 및 R 10은 각각 H 또는 C 1-6 알킬이거나, 또는 R 9와 R 10은 서로 결합하여 이들이 결합된 탄소 원자와 함께 시클로알킬을 형성하고, R 11은 시아노, 비치환 또는 C 1-6 알킬 치환 헤테로아릴, 헤테로사이클릴 또는 -C(O)NR 20R 21이고, 여기서 R 20은 H 또는 C 1-6 알킬이고, R 21은 H, 비치환 또는 히드록시 치환 C 1-6 알킬, 시클로알킬, 아릴, 또는 비치환 또는 C 1-6 알킬 치환 헤테로아릴이거나, 또는 R 20과 R 21은 서로 결합하여 이들이 결합된 N 원자와 함께 헤테로사이클릴을 형성하는 것인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 있어서, 상기 아릴이 페닐인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 있어서, 상기 헤테로아릴이 피롤릴, 피라졸릴, 이미다졸릴, 테트라졸릴, 옥사졸릴, 티에닐, 이속사졸릴, 티아졸릴, 이소티아졸릴, 티아디아졸릴, 옥사디아졸릴, 퓨라닐, 티오페닐, 피리디닐, 피리다지닐, 피리미딜, 트리아지닐, 피라지닐 및 피리딘-N-옥시드로 구성된 군에서 선택되는 것인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 있어서, 상기 헤테로사이클릴이 테트라하이드로피라닐, 테트라하이드로퓨라닐, 디하이드로퓨라닐, 디하이드로피라닐, 테트라하이드로피리디닐, 디옥사닐, 디티아닐, 디옥솔라닐, 이미다졸리디닐, 이미다졸리닐, 피롤리닐, 피페라지닐, 몰포리닐, 티오몰포리닐, 피페리디닐, 옥세타닐, 피롤리디닐 및 아제파닐로 구성된 군에서 선택되는 것인 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 있어서,1) N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;2) 4-(3-아미노페닐)-2-(4-(트리플루오로메틸)페틸)프탈라진-1(2H)-온;3) N-(3-(4-옥소-3-(4-(트리플루오로메틸)페닐)-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;4) 4-(3-(에틸아미노)페닐)-2-(4-(트리플루오로메틸)페닐)프탈라진-1(2H)-온;5) N-메틸-N-(3-(4-옥소-3-(4-(트리플루오로메틸)페닐)-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;6) N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드;7) N-메틸-N-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드;8) N-(4-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;9) N-(3-(3-페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-디메틸설파모일아미드;10) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드;11) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;12) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-디메틸설파모일아미드;13) (Z)-N-메틸-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;14) (Z)-N-이소프로필-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;15) (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;16) (Z)-N-에틸-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;17) (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;18) N-(2-클로로-5-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)-N-(메틸설포닐)메탄설폰아미드;19) N-(3-(3-(페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-6-클로로페닐)-디메틸설파모일아미드;20) 메틸 (N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)설파모일)카바메이트;21) (Z)-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;22) (Z)-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;23) (Z)-N-터트-부틸-1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;24) 4-(3-아미노페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온;25) N-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;26) 메틸 (N-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)설파모일)카바메이트;27) (Z)-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;28) Z)-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;29) (Z)-N-터트-부틸-1-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;30) N-(3-(3-(3-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;31) (Z)-1-(3-(3-(3,5-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;32) (Z)-N-이소프로필-1-(3-(3-(4-메톡시페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;33) (Z)-1-(3-(3-(3-클로로-4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;34) (Z)-N-터트-부틸-1-(3-(3-(3-클로로-4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;35) (Z)-N-벤질l-1-(3-(4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;36) (E)-1-(4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;37) (Z)-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;38) (E)-1-(3-플루오로-4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;39) (E)-1-(3-플루오로-4-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;40) (Z)-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;41) (Z)-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;42) (Z)-N-터트-부틸-1-(2-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;43) (Z)-N-터트-부틸-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;44) (Z)-N-벤질-1-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;45) (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)-N-메틸메탄이민 옥시드;46) (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)-N-이소프로필메탄이민 옥시드;47) (Z)-N-터트-부틸-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)티오펜-2-일)메탄이민 옥시드;48) (Z)-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)퓨란-2-일)-N-이소프로필메탄이민 옥시드;49) (Z)-N-터트-부틸-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-2-메톡시페닐)메탄이민 옥시드;50) (Z)-N-벤질-1-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-2-메톡시페닐)메탄이민 옥시드;51) (Z)-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;52) (Z)-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;53) (Z)-N-터트-부틸-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;54) (Z)-N-벤질-1-(2-플루오로-5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;55) (Z)-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;56) (Z)-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;57) (Z)-N-터트-부틸-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;58) (Z)-N-벤질-1-(4-플루오로-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;59) 4-(4-클로로-3-니트로페닐)-2-(4-플루오로페닐)프탈라진-1(2H)-온;60) 4-(3-아미노페닐)-2-(4-플루오로페닐)프탈라진-1(2H)-온;61) N-(3-(3-벤질-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;62) N-(3-(4-옥소-3-페네틸-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;63) N-(3-(3-(4-플루오로벤질)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;64) N-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;65) N-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸에탄설폰아미드;66) 메틸 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤조에이트;67) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)프로판-2-설폰아미드;68) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)프로판-1-설폰아미드;69) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄설폰아미드;70) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸에탄설폰아미드;71) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판설폰아미드;72) N-(3-(3-(4-플로오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸프로판-1-설폰아미드;73) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸프로판-2-설폰아미드;74) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸시클로프로판설폰아미드;75) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸-디메틸설파모일아미드;76) 메틸 (N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸설파모일)(메틸)카바메이트;77) 1,1,1-트리플루오로-N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄설폰아미드;78) 1,1,1-트리플루오로-N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄설폰아미드;79) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-((테트라하이드로-2H-피란-2-일)옥시)벤즈아미드;80) N-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸-메틸설파모일아미드;81) 4-(3-(1H-테트라졸-5-일)페닐)-2-(4-플루오로페닐)프탈라진-1(2H)-온;82) N-(5-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘-3-일)에탄설폰아미드;83) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-히드록시벤즈아미드;84) (Z)-1-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;85) (Z)-1-(3-(3-([1,1'-비페닐]-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;86) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;87) N-에틸-3-(3-(4-플로오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드;88) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메일벤젠설폰아미드;89) 2-(2,4-디플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;90) 2-(2,4-디플루오로페닐)-4-(3-(에틸설폰닐)페닐)프탈라진-1(2H)-온;91) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;92) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드;93) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드;94) (Z)-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;95) (Z)-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;96) (Z)-N-터트-부틸-1-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;97) 2-(2-플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;98) 4-(3-(에틸설포닐)페닐)-2-(2-플루오로페닐)프탈라진-1(2H)-온;99) 3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;100) N-에틸-3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드;101) 3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드;102) (Z)-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-메틸메탄이민 옥시드;103) (Z)-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-이소프로필메탄이민 옥시드;104) (Z)-N-터트-부틸-1-(3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)메탄이민 옥시드;105) 2-(2,6-디플루오로페닐)-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;106) 2-(2,6-디플루오로페닐)-4-(3-(에틸설포닐)페닐)프탈라진-1(2H)-온;107) 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;108) 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드;109) 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드;110) 6-플루오로-4-(3-(메틸설포닐)페닐)-2-페닐프탈라진-1(2H)-온;111) 3-(7-플루오로-4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;112) 7-플루오로-4-(3-(메틸설포닐)페닐)-2-페닐프탈라진-1(2H)-온;113) 3-(6-플루오로-4-옥소-3-페닐-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;114) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드;115) 2-(2,4-디플루오로페닐)-4-(피리딘-3-일)프탈라진-1(2H)-온;116) 2-(2,6-디플루오로페닐)-4-(피리딘-3-일)프탈라진-1(2H)-온;117) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드;118) 3-(3-(2,6-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피리딘 1-옥시드;119) 2-(2,4-디플루오로페닐)-6-플루오로-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;120) 2-(2,4-디플루오로페닐)-7-플루오로-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;121) 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;122) 3-(3-(2,4-디플루오로페닐)-6-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-메틸벤젠설폰아미드;123) 2-(2,4-디플루오로페닐)-4-(3-(에틸설포닐)페닐)-6-플루오로프탈라진-1(2H)-온;124) 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸벤젠설폰아미드;125) 3-(3-(2,4-디플루오로페닐)-7-플루오로-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디메틸벤젠설폰아미드;126) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드;127) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-(2-히드록시에틸)벤젠설폰아미드;128) N-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;129) N-(3-(3-(1-메틸피페리딘-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;130) 3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)벤조니트릴;131) (E)-3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N'-히드록시벤즈이미드아미드;132) N-(3-(3-이소프로필-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;133) N-(3-(3-(1-메틸-1H-피라졸-4-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탈설폰아미드;134) 4-(3-아미노피페리딘-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;135) N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드;136) N-(3-(3-(옥세탄-3-일)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;137) N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피롤리딘-3-일)에탄설폰아미드;138) (S)-N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드;139) (R)-N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드;140) N-(3-(3-(4,4-디플루오로시클로헥실)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;141) N-(1-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드;142) 3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)벤젠설폰아미드;143) 4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드;144) N-(1-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드;145) N-(3-(3-(4-메틸시클로헥실)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;146) (S)-4-(3-아미노피페리딘-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드;147) (S)-N-(1-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)에탄설폰아미드;148) 4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;149) N-(3-(2-(4-플루오로페닐)-1-옥소-1,2-디하이드로피리도[3,4-d]피리딘-4-일)페닐)에탄설폰아미드;150) N-(3-(3-(4-플루오로페닐)-8-메틸-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;151) N-(3-(4-옥소-3-(테트라하이드로-2H-피란-4-일)-3,4-디하이드로프탈라진-1-일)페닐)에탄설폰아미드;152) 2-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;153) 2-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N,2-디메틸프로판아미드;154) 2-시클로헥실-4-(3-(메틸설포닐)페닐)프탈라진-1(2H)-온;155) (S)-4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드;156) (S)-2-시클로헥실-4-(3-(메틸아미노)아제판-1-일)프탈라진-1(2H)-온·하이드로클로라이드;157) (S)-4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;158) (S)-4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;159) (R)-4-(3-아미노아제판-1-일)-2-시클로헥실프탈라진-1(2H)-온·하이드로클로라이드;160) 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;161) 3-(3-(3-(4-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)옥사졸리딘-2-온;162) (R)-4-(3-아미노아제판-1-일)-2-(4-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;163) 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;164) 2-(3-(3-시클로헥실-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N,2-디메틸프로판아미드;165) (R)-4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;166) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;167) 4-(3-아미노아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;168) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판니트릴;169) 4-(3-(2-(1H-테트라졸-5-일)프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온;170) (E)-2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N'-히드록시-2-메틸프로판이미드아미드;171) 2-(3-(3-(2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;172) 4-(3-아미노아제판-1-일)-2-시클로부틸프탈라진-1(2H)-온·하이드로클로라이드;173) 4-(3-아미노아제판-1-일)-2-시클로펜틸프탈라진-1(2H)-온·하이드로클로라이드;174) 2-(2,4-디플루오로페닐)-4-(3-(2-(5-메틸-1,2,4-옥사디아졸-3-일)프로판-2-일)페닐)프탈라진-1(2H)-온;175) (R)-4-(3-아미노아제판-1-일)-2-(2-플루오로페닐)프탈라진-1(2H)-온·하이드로클로라이드;176) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)페닐)-N-이소프로필-2-메틸프로판아미드;177) 2-(2,4-디플루오로페닐)-4-(3-(2-메틸-1-옥소-1-(피롤리딘-1-일)프로판-2-일)페닐)프탈라진-1(2)-온;178) N-사이클로프로필-2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;179) 2-(2,4,-디플루오로페닐)-4-(3-(2-메틸-1-몰폴리노-1-옥소프로판-2-일)페닐)프탈라진-1(2H)-온;180) N-시클로헥실-2-(3-(3-(2,4-디플루오페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;181) N-시클로헥실-2-(3-(3-(2,4-디플루오페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;182) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)페닐)-2-메틸-N-(1-메틸-1H-피라졸-4-일)프로판아미드;183) 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복실산;184) 4-(1,4-디아제판-1-일)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드;185) (R)-4-(3-아미노아제판-1-일)-2-(4-클로로페닐)프탈라진-1(2H)-온 하이드로클로라이드;186) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-N-(2-히드록시에틸)-2-메틸프로판아미드;187) (R)-N-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)에탄설폰아미드;188) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;189) (R)-2-(2,4-디플루오루페닐)-4-(3-(메틸아미노)아제판-1-일)프탈라진-1(2H)-온 하이드로클로라이드;190) (R)-2-(2,4-디플루오루페닐)-4-(3-(메틸아미노)아제판-1-일)프탈라진-1(2H)-온 하이드로클로라이드;191) (R)-2-(2,4-디플루오로페닐)-4-(3-((2-히드록시에틸)아미노)아제판-1-일)프탈라진-1(2H)-온 하이드로클로라이드;192) (R)-N-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-일)아세트아미드;193) 2-(2,4-디플루오로페닐)-4-(3-옥소아제판-1-일)프탈라진-1(2H)-온;194) 2-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;195) 1-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복실산;196) 2-(4-클로로페닐)-4-(3-히드록시아제판-1-일)프탈라진-1(2H)-온;197) 2-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로판아미드;198) 1-(3-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로프로판-1-카복시아미드;199) 2-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)아세트산;200) 4-(3-(2-아미노프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드;201) 2-(3-(3-(4-클로로-2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;202) (R)-4-(3-아미노아제판-1-일)-2-(4-클로로-2-플루오로페닐)프탈라진-1-(2H)-온 하이드로클로라이드;203) 1-(3-(4-클로로-2-플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)아제판-3-카보니트릴;204) 4-(3-(1-아미노-2-메틸프로판-2-일)페닐)-2-(2,4-디플루오로페닐)프탈라진-1(2H)-온 하이드로클로라이드;205) 2-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산;206) 2-(3-(3-(4-시클로프로필페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)-2-메틸프로피온산;207) 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로부탄-1-카복실산;208) 1-(3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)페닐)시클로부탄-1-카복실산;209) 2-(1-(3-(4-클로로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산;210-1 및 210-2) 2-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)-2-메틸프로피온산;211) 메틸 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실레이트;212) 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실산;213-1 및 213-2) 1-(1-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)피페리딘-3-일)시클로프로판-1-카복실산;214) 2-(2,4-디플루오로페닐)-4-(3-(피롤리딘-1-일설포닐)페닐)프탈라진-1(2H)-온;215) 2-(2,4-디플루오로페닐)-4-(1,2,3,6-테트라하이드로피리딘-4-일)프탈라진-1(2H)-온 하이드로클로라이드;216) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N-에틸-N-메틸벤젠설폰아미드;217) 3-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-N,N-디에틸벤젠설폰아미드;218) 2-(2,4-디플루오로페닐)-4-(1-(에틸설포닐)-1,2,3,6-테트라하이드로피리딘-4-일)프탈라진-1(2H)-온;219) 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디히들프탈라진-1-일)피페라진-2-일)-2-메틸프로피온산;220) 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4-디하이드로프탈라진-1-일)-1-메틸피페라진-2-일)-2-메틸프로피온산, 및221) 2-(4-(3-(2,4-디플루오로페닐)-4-옥소-3,4,-디하이드로프탈라진-1-일)몰포린-2-일)-2-메틸프로피온산으로 구성된 군에서 선택되는 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염.
- 제1항에 따른 화합물, 또는 이의 라세미체, 입체이성질체 또는 약학적으로 허용 가능한 염을 포함하는 Sirt6 관련 질환의 예방 또는 치료용 약학적 조성물.
- 제14항에 있어서, Sirt6 관련 질환은 암, 지방간, 간경화/염증, 인슐린 분비 저하 및 노화 관련 질환으로 구성된 군에서 선택되는 것인 약학적 조성물.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080032105.9A CN113840820B (zh) | 2019-05-29 | 2020-05-29 | 酞嗪酮化合物及其用途 |
US17/594,754 US20220235011A1 (en) | 2019-05-29 | 2020-05-29 | Phthalazinone compounds and use thereof |
KR1020217035260A KR102588822B1 (ko) | 2019-05-29 | 2020-05-29 | 프탈라진온 화합물 및 이들의 용도 |
JP2021564330A JP7416558B2 (ja) | 2019-05-29 | 2020-05-29 | フタラジノン化合物およびこれらの用途 |
EP20814110.1A EP3978480A4 (en) | 2019-05-29 | 2020-05-29 | PHTHALAZINONE COMPOUNDS AND THEIR USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2019-0063436 | 2019-05-29 | ||
KR20190063436 | 2019-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020242245A1 true WO2020242245A1 (ko) | 2020-12-03 |
Family
ID=73552390
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2020/006995 WO2020242245A1 (ko) | 2019-05-29 | 2020-05-29 | 프탈라진온 화합물 및 이들의 용도 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20220235011A1 (ko) |
EP (1) | EP3978480A4 (ko) |
JP (1) | JP7416558B2 (ko) |
KR (1) | KR102588822B1 (ko) |
CN (1) | CN113840820B (ko) |
WO (1) | WO2020242245A1 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057650A (zh) * | 2021-11-08 | 2022-02-18 | 温州大学 | 一种一锅法制备4,5-二氢哒嗪-3-酮类化合物的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624922A (en) * | 1990-09-10 | 1997-04-29 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
WO2016139361A1 (en) * | 2015-03-05 | 2016-09-09 | Boehringer Ingelheim International Gmbh | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2531776A1 (de) * | 1975-07-16 | 1977-02-03 | Basf Ag | Azopigmente mit einem phthalazonrest |
JP3130671B2 (ja) * | 1992-08-06 | 2001-01-31 | 株式会社東海 | 容器の保持装置 |
CA2104060A1 (en) * | 1992-11-10 | 1994-05-11 | Robert Ed Johnson | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
EP0634404A1 (en) * | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Phtalazin derivatives and their use as pesticides |
JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
US20130190309A1 (en) * | 2008-12-16 | 2013-07-25 | Chi B. Vu | Phthalazinone and related analogs as sirtuin modulators |
CN109280032B (zh) * | 2017-07-19 | 2023-05-12 | 中国科学院上海药物研究所 | 一种哒嗪酮母核结构的组蛋白去乙酰化酶抑制剂及其制备方法和用途 |
-
2020
- 2020-05-29 CN CN202080032105.9A patent/CN113840820B/zh active Active
- 2020-05-29 US US17/594,754 patent/US20220235011A1/en active Pending
- 2020-05-29 WO PCT/KR2020/006995 patent/WO2020242245A1/ko unknown
- 2020-05-29 EP EP20814110.1A patent/EP3978480A4/en active Pending
- 2020-05-29 JP JP2021564330A patent/JP7416558B2/ja active Active
- 2020-05-29 KR KR1020217035260A patent/KR102588822B1/ko active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5624922A (en) * | 1990-09-10 | 1997-04-29 | Sterling Winthrop Inc. | Aryl-fused and hetaryl-fused-2,4-diazepine and 2,4-diazocine antiarrhythmic agents |
WO2016139361A1 (en) * | 2015-03-05 | 2016-09-09 | Boehringer Ingelheim International Gmbh | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
Non-Patent Citations (20)
Title |
---|
CELL METAB, vol. 12, 2010, pages 224 - 236 |
CELL, vol. 136, 2009, pages 62 - 74 |
CELL, vol. 140, 2010, pages 280 - 293 |
CELL, vol. 151, 2012, pages 1185 - 1199 |
CURR. TOP. MED. CHEM., vol. 13, 2013, pages 2991 - 3000 |
CYCLE, vol. 8, 2009, pages 2664 - 2666 |
DATABASE Registry CAS; 1 March 2018 (2018-03-01), "- 1(2H)-Phthalazinone, 7-chloro-4-phenyl-2-propyl-", XP055764787, retrieved from STN Database accession no. RN 2182402-34-0 * |
DATABASE Registry CAS; 3 January 2003 (2003-01-03), "- 1(2H)-Phthalazinone, 2-(4-bromophenyl)-7-fluoro-4-(4-fluorophenyl)-", XP055764759, retrieved from STN Database accession no. RN 478066-05-6 * |
DATABASE Registry CAS; 30 May 2001 (2001-05-30), "- 1(2H)-Phthalazinone, 7-fluoro-2,4-bis(4-fluorophenyl)-", XP055764773, retrieved from STN Database accession no. RN 339009-71-1 * |
DATABASE Registry CAS; 30 May 2001 (2001-05-30), "- 1(2H)-Phthalazinone, 7-fluoro-4-(4-fluorophenyl)-2-[4- (trifluoromethyl)phenyl]-", XP055764768, retrieved from STN Database accession no. RN 339009-72-2 * |
DATABASE Registry CAS; 4 March 2018 (2018-03-04), "- 1(2H)-Phthalazinone, 7-chloro-2,4-diphenyl-", XP055764784, retrieved from STN Database accession no. RN2183741-74-2 * |
DATABASE Registry CAS; 4 March 2018 (2018-03-04), "1(2H)-Phthalazinone, 8-chloro-2,4-diphenyl-", XP055764779, retrieved from STN Database accession no. RN2184101-07-1 * |
HAMEED, A. DH. ET AL.: "Synthesis and Biological Evaluation of New Phthalazinone Derivatives as Anti-Inflammatory and Anti-Proliferative Agents", ARCH. PHARM. CHEM. LIFE SCI., vol. 349, 2016, pages 150 - 159, XP055861161 * |
J. BIOL. CHEM., vol. 287, 2012, pages 41903 - 41913 |
NAT. STRUCT. MOL. BIOL., vol. 23, 2016, pages 434 - 440 |
NATURE, vol. 452, 2008, pages 492 - 496 |
NATURE, vol. 460, 2009, pages 587 - 591 |
PROC. NATL. ACAD. SCI. U S A., vol. 107, 2010, pages 21790 - 21794 |
SCI. REP., vol. 3, 2013, pages 3085 |
See also references of EP3978480A4 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057650A (zh) * | 2021-11-08 | 2022-02-18 | 温州大学 | 一种一锅法制备4,5-二氢哒嗪-3-酮类化合物的方法 |
CN114057650B (zh) * | 2021-11-08 | 2023-03-28 | 温州大学 | 一种一锅法制备4,5-二氢哒嗪-3-酮类化合物的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP2022530528A (ja) | 2022-06-29 |
CN113840820B (zh) | 2024-05-03 |
CN113840820A (zh) | 2021-12-24 |
EP3978480A1 (en) | 2022-04-06 |
JP7416558B2 (ja) | 2024-01-17 |
KR102588822B1 (ko) | 2023-10-19 |
EP3978480A4 (en) | 2023-10-25 |
KR20210137216A (ko) | 2021-11-17 |
US20220235011A1 (en) | 2022-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011043568A2 (en) | Novel compounds effective as xanthine oxidase inhibitors, method for preparing the same, and pharmaceutical composition containing the same | |
WO2016032120A1 (ko) | 신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도 | |
WO2012115479A2 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
AU2019310508B2 (en) | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same | |
WO2012115480A2 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
AU2012221927A1 (en) | Diaminopyrimidine derivatives and processes for the preparation thereof | |
WO2015034271A1 (en) | Novel antifungal pyridinylhydrazide derivatives | |
EP2906558A1 (en) | Sodium channel blockers, preparation method thereof and use thereof | |
AU2019381113B2 (en) | Novel compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof | |
WO2018226053A1 (ko) | 시클로프로필아민 유도체 화합물 및 이의 용도 | |
WO2022250350A1 (ko) | 피페리딘디온 유도체 | |
WO2020242245A1 (ko) | 프탈라진온 화합물 및 이들의 용도 | |
WO2022050749A1 (ko) | 디아실글리세롤 아실트랜스퍼라제 2 억제제로서 유용한 신규 바이아릴 유도체 및 이의 용도 | |
WO2021040393A1 (ko) | 인돌 카복사미드 유도체 및 그를 포함하는 약제학적 조성물 | |
WO2011122815A2 (en) | Novel quinoxaline derivatives | |
EP3060549A1 (en) | Novel antifungal oxodihydropyridinecarbohydrazide derivative | |
WO2021137665A1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
WO2021034087A1 (ko) | 신규한 암전이 억제 활성을 갖는 화합물, 이의 제조방법 및 상기 화합물을 포함하는 암 전이 및 침윤 억제, 또는 대장암 치료용 약학적 조성물 | |
WO2017119570A1 (ko) | 티아졸리딘디온 유도체 및 그의 용도 | |
EP3867249A1 (en) | Novel (isopropyl-triazolyl)pyridinyl-substituted benzooxazinone or benzothiazinone derivatives and use thereof | |
WO2018021762A1 (ko) | 신규 화합물, 이의 제조방법 및 이를 포함하는 약학 조성물 | |
WO2023090908A1 (ko) | 신규 플라보노이드 유도체 및 이를 유효성분으로 포함하는 대사성 질환의 예방 또는 치료용 약학 조성물 | |
WO2019235894A1 (ko) | Aimp2-dx2와 k-ras의 결합을 저해하는 화합물을 포함하는 고형암 예방 또는 치료용 조성물 및 aimp2-dx2와 k-ras의 결합을 저해하는 신규 화합물 | |
WO2022164135A1 (ko) | 벤조티아졸 및 벤즈이미다졸 유도체, 약제학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 | |
WO2022255764A1 (ko) | 신규 옥사졸 유도체 및 이를 포함하는 알러지성 질환의 예방 또는 치료용 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20814110 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021564330 Country of ref document: JP Kind code of ref document: A Ref document number: 20217035260 Country of ref document: KR Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2020814110 Country of ref document: EP Effective date: 20220103 |